

Report for the Nine Months Ended March 31, 2025 Shaping Tomorrow



Contents

0

Company Information

Unconsolidated Condensed Interim Financial Information

Review of the Directors Unconsolidated (English/ اردو))	03
Statement of Financial Position	19
Statement of Profit or Loss	20
Statement of Comprehensive Income	21
Statement of Changes in Equity	22
Statement of Cash Flows	23
Notes to and Forming Part of the Financial Statements	24

Consolidated Condensed Interim Financial Information

Review of the Directors Consolidated (English/اروو))	38
Statement of Financial Position	40
Statement of Profit or Loss	41
Statement of Comprehensive Income	42
Statement of Changes in Equity	43
Statement of Cash Flows	44
Notes to and Forming Part of the Financial Statements	45

02

Company Information

Board of Directors

Muhammad Sohail Tabba – Chairman (Non-Executive Director) Muhammad Ali Tabba – Vice Chairman (Non-Executive Director) Jawed Yunus Tabba – Non-Executive Director Amina A. Aziz Bawany – Non-Executive Director Asif Jooma – Chief Executive (Executive Director) Adnan Afridi – Independent Director Syed Muhammad Shabbar Zaidi – Independent Director Ariful Islam – Independent Director

Audit Committee

Syed Muhammad Shabbar Zaidi – Chairman Adnan Afridi – Member Muhammad Ali Tabba – Member Jawed Yunus Tabba – Member

HR & Remuneration (HR&R) Committee

Adnan Afridi – Chairman Muhammad Sohail Tabba – Member Muhammad Ali Tabba – Member Jawed Yunus Tabba – Member Asif Jooma – Member

Banking Committee

Asif Jooma – Chairman Adnan Afridi – Member Ariful Islam – Member

Executive Management Team (EMT)

Asif Jooma – Chief Executive Atif Aboobukar – Chief Financial Officer* Nauman Shahid Afzal – Chief Operating Officer, Chemicals & Agri Sciences Business Laila Bhatia Bawany – Chief Legal Officer & Company Secretary Rizwan Afzal Chaudhry – Chief Operating Officer, Polyester Business Himra Mursil – Chief People Officer** Muhammad Umar Mushtaq – Chief Operating Officer, Soda Ash Business Atif Siddiqui – Chief Operating Officer, Pharmaceuticals Business

*Alphabetised as per the last name ** Joined with effect from February 3, 2025

Chief Financial Officer Atif Aboobukar

Company Secretary Laila Bhatia Bawany

Head of Internal Audit Khalid Munif Khan

Bankers

Al Baraka Bank (Pakistan) Limited Allied Bank Limited Allied Bank Limited - Islamic Banking Group Askari Bank Limited Askari Ikhlas – Islamic Banking Bank Al Habib Limited Bank Al Habib - Islamic Banking Bank Alfalah Limited Bank Alfalah Limited - Islamic Banking Group Bank Islami Pakistan Limited Bank of Khyber Bank of Punjab Faysal Bank Limited Habib Bank Limited Habib Bank Limited - Islamic Banking Habib Metropolitan Bank Limited Habib Metropolitan Bank – Sirat Islamic Industrial and Commercial Bank of China Limited MCB Bank Limited MCB Islamic Bank Limited Meezan Bank Limited National Bank of Pakistan Samba Bank Limited Standard Chartered Bank (Pakistan) Limited Standard Chartered Bank (Pakistan) Limited - Saadiq United Bank Limited **UBL** Ameen

Registered Office

5 West Wharf, Karachi – 74000. Tel: 111-100-200 / (021) 32313717-22 | Fax: (021) 32311739 Website: www.luckycore.com

Share Registrar

FAMCO Share Registration Services (Private) Limited 8 – F, Nursery, Block – 6, P.E.C.H.S Shahrah-e-Faisal, Karachi. Tel: (021) 34380101-5 | Fax: (021) 34380106 Website: www.famcosrs.com

External Auditors

A.F. Ferguson & Co. Chartered Accountants

Legal Advisor

Imran Mushtaq & Company 78 – B, Mozang Road (Opp. British Council), Lahore. Tel: (042) 36298184-5 | Fax: (042) 36298186

Review of the Directors (Unconsolidated)

for the Nine Months ended March 31, 2025

The Directors are pleased to present their review, together with the unaudited financial statements of the Company, for the quarter and nine-months ended March 31, 2025.

Net Turnover for the quarter at PKR 29,821 million is 4% lower than the same period last year (SPLY). Net Turnover for the Pharmaceuticals Business is 62% higher as compared to the SPLY, whereas demand compression in the Soda Ash, Polyester, Animal Health and Chemicals & Agri Sciences Businesses resulted in a decline of 16%, 10%, 11% and 3% respectively compared to the SPLY.

The Operating Result for the quarter at PKR 4,269 million is 6% lower than the SPLY. The Pharmaceuticals and Animal Health Businesses delivered higher Operating Results by 80% and 8% respectively as compared to the SPLY, whereas due to a slowdown in domestic market, the Soda Ash, Polyester and Chemicals & Agri Sciences Businesses posted a decline in Operating Results by 22%, 27% and 1% respectively as compared to the SPLY. The Soda Ash Business was particularly impacted by lower domestic and regional prices, as well as below-forecast sales volumes.

Net Turnover for the nine-month period under review at PKR 92,093 million is 1% higher compared to the SPLY. Net Turnover of the Pharmaceuticals and Polyester Businesses increased by 74% and 5% respectively as compared to the SPLY, whereas the Soda Ash, Animal Health and Chemicals & Agri Sciences Business witnessed a decline of 17%, 12% and 5% respectively as compared to the SPLY.

The Operating Result for the nine-month period under review at PKR 13,609 million is 8% higher than the SPLY. The Pharmaceuticals and Polyester Businesses delivered higher Operating Results by 122% and 31% respectively as compared to the SPLY. The operating performance of the Animal Health Business remained almost in line with the SPLY, whereas the Soda Ash and Chemicals & Agri Sciences Businesses posted a decline in Operating Results by 15% and 11% respectively as compared to the SPLY.

Growth in the Pharmaceuticals Business performance was supported by the seamless integration of the assets acquired from Pfizer Pakistan Limited and other relevant Pfizer group entities, marking a significant milestone for the Company. The base business performance was driven by recovery in margins benefiting from an improvement and stability in the value of the Pak Rupee, inflation related price adjustments of certain non-essential medicines, improvement in sales mix, and continued focus on operational efficiencies.

The Polyester Business's improved performance was driven by elevated global freight costs in the first half of the FY 24-25, which made imported PSF more expensive, improved sales of specialised variants and improved operational efficiencies. The Soda Ash Business continued to be impacted by subdued local demand across major segments. Additionally, export sales suffered significantly due to lower export price and higher freight costs making export sales economically unviable. The Chemicals & Agri Sciences and Animal Health Businesses faced challenges on the demand front driven by weak consumer purchasing power.

On September 6, 2024, the Company completed an asset acquisition with Pfizer Pakistan Limited and other relevant Pfizer group entities (Please refer to note 5 of the Financial Statements for the nine-months ended March 31, 2025). The transaction entailed the sale and purchase of a manufacturing facility, selected pharmaceutical products, and associated trademarks (either through an outright assignment of trademarks or a perpetual license to use the relevant trademarks from relevant Pfizer group entities).

Profit After Tax (PAT) for the nine-month period under review at PKR 8,805 million is 11% higher than the SPLY primarily on account of higher Operating Results and lower finance cost attributable to a 600 basis points reduction in average policy rate compared to the SPLY. The performance was achieved despite increase in the effective tax rate resulting from the change in taxation regime on exports effective July 1, 2024.

PKR million	Nine Months Ended March, 2025	Nine Months Ended March, 2024	Increase/ (Decrease) %
Net Turnover	92,093	91,281	1%
Gross Profit	20,889	19,821	5%
Operating Result	13,609	12,598	8%
Profit Before Taxation	14,069	12,080	16%
Profit After Taxation	8,805	7,933	11%
Earnings Per Share (PKR)	95.34	85.89	11%

Net Turnover (PKR m)



Profit Before Tax (PKR m)



Profit After Tax (PKR m)



Earnings Per Share (PKR)



Polyester Staple Fibre Business (PSF)

Net Turnover (PKR m)



During the nine-month period under review, global commodity markets continued to face challenges due to slower-thanexpected demand recovery in both China and the US. In China, demand remained subdued as households sustained reduced spending, reflecting ongoing cost-cutting measures.

During the period under review, the average crude oil price declined by 9% compared to the SPLY. Consequently, the PX and PTA markets experienced declines of 15% and 13%, respectively. The MEG market, however, demonstrated resilience amid declining inventories, achieving an average price increase of 10% compared to the SPLY.

On the cotton front, improved availability kept the international cotton prices under pressure, as they declined by 20% compared to the SPLY. Also, due to availability of imported cotton in the market, domestic cotton prices decreased by 4% as compared to the SPLY.

During the nine-month period under review, the Net Turnover increased by 5% compared to the SPLY. Operating Result, at PKR 1,719 million, increased by 31% compared to the SPLY.

Operating Result (PKR m)



Despite rising energy costs, driven primarily by high reliance on imported RLNG, the business was able to improve its operating profit. This performance was largely underpinned by increased sales of specialised fibre variants, including CICLO, Repreve and Anti-microbial fibre. Additionally, the performance was supported by high global freight rates in the first half of the FY 24-25, allowing better local margins compared to imports, and a focus on cost management.

Looking ahead, crude oil prices are expected to remain volatile due to the impact of U.S reciprocal tariff shock, and the feedstock markets are expected to follow crude oil trends. The tariff pressure on the Chinese exports will push China to move focus elsewhere and that may result in further dumping in the region including Pakistan. Any further increase in the dumped imports will pose even bigger competitive challenge for the PSF and downstream spinning industry. Active engagement of Pakistan's commerce ministry team with the US tariff team will be required to negotiate a more reasonable tariff with longer timeline to allow industry to adjust.

6

Soda Ash Business

Net Turnover (PKR m)



The global soda ash market continued to remain subdued, mainly due to weakened demand and oversupply conditions, particularly in China. Chinese producers continued to export at negative margins to maintain operating rates, amid stagnant demand from key sectors, including a slowdown in construction activity and the impact of tariffs on solar panels.

During the nine-month period under review, the Soda Ash Business delivered a Net Turnover of PKR 30,063 million and Operating Result of PKR 6,180 million, which are 17% and 15% lower than the SPLY respectively. This is despite enhanced installed capacity of 560,000 tonnes having been commissioned in the previous year.

During the period under review, the domestic soda ash market remained under stress. Domestic sales declined by 9% compared to the SPLY, owing to a weak demand from key segments amid reduced purchasing power. Exports were 42% lower than the SPLY as prices continue to remain low on account of the slowdown in the international market, resulting in reduced margins and volumes. Additionally, to maintain operating rates the

Operating Result (PKR m)



business was forced to export product at breakeven and in some cases at negative margin to match offers from Turkey and China.

Imports, particularly from Turkey at dumped prices, further impacted domestic manufacturers sales. The Company continues to make appropriate representations for corrective measures before the National Tariff Commission and Ministry of Commerce failing which there is likely to be irreparable damage to the local manufacturers.

On the domestic front, the overall economic landscape remained challenging with the domestic market continuing to operate below capacity due to subdued demand. Despite the positive developments from the new IMF package and easing inflation, sustainable economic growth remains unlikely without structural reforms and fiscal discipline.

On the exports front, international prices remain under pressure due to ample supply and subdued demand with Chinese producers continuing to export at negative margins to maintain plant operating rates.

Pharmaceuticals Business

Net Turnover (PKR m)



The Net turnover of the Pharmaceuticals Business at PKR 15,536 million for the nine-months under review is 74% higher compared to the SPLY, and the Operating Result at PKR 3,427 million is 122% higher than the SPLY.

During the nine-months under review, a major achievement for the Pharmaceuticals Business was the seamless integration of the portfolio acquired from Pfizer entities, marking a significant milestone for growth. This acquisition has enriched the existing product portfolio, expanded the business's market reach, and will continue to drive sustained growth through increased operational synergies and improved access to products in key therapeutic areas. Furthermore, price adjustments for non-essential medicines have allowed market dynamics to adjust pricing, providing manufacturers greater flexibility to manage rising costs. The sector, however, continues to encounter challenges with respect to the

Operating Result (PKR m)



economic sustainability of essential life-saving drugs due to rising costs and inadequate price adjustments.

Despite the challenges, LCI's Pharmaceuticals Business has mitigated cost increases by launching new products to address unmet market demands, enhancing manufacturing efficiencies, and optimising working capital.

Looking ahead, the Pharmaceuticals Business is well-positioned to sustain its growth momentum, leveraging its strong market presence and a forward-looking approach. However, there remains an urgent need for a more sustainable regulatory framework for essential medicines. The imposition of higher taxes on exports and duties on essential raw materials has increased cost pressures. A more balanced regulatory approach is crucial to ensure the continued supply and affordability of these essential medicines.

Animal Health Business

Net Turnover (PKR m)



The Net Turnover of the Animal Health Business at PKR 4,498 million for the nine-months under review is 12% lower compared to the SPLY and the Operating Result at PKR 783 million is in line with SPLY.

The Animal Health industry in Pakistan is adapting to an evolving business environment, marked by escalating farm management costs due to the imposition of sales tax on feed, rising maize prices, higher costs for day-old chicks, and increased energy costs limiting the farmer's ability to invest in essential animal feed and medicines.

In the livestock sector, the demand for antibiotics, dewormers, and reproductive solutions remained high. Dairy farmers are prioritising effective herd management during peak lactation to optimise milk production and improve fertility. Additionally, growing demand for Bovine Genetic portfolio highlighted the sector's emphasis on enhancing herd quality and productivity. Government initiatives, such as the Livestock Card in Punjab, have helped support farmers by facilitating access to essential feed and veterinary care. However, the sales tax on feed items continues to impact the livestock feed market, benefiting unregistered vendors.

Operating Result (PKR m)



The Poultry sector experienced increased chicken prices due to limited availability of day-old chicks during high seasonal demand. Viral outbreaks, particularly Avian Influenza, have driven demand for flu vaccines, while secondary bacterial infections have led to increased demand for antibiotics, enabling the business to improve its share in both biologicals and antibiotic segments.

Despite a 25% and 20% decline in the poultry and livestock markets respectively, compared to the SPLY, the business showed resilience through product optimisation, efficiency gains, and cost control. Looking ahead, adverse weather conditions and a Foot-and-Mouth Disease outbreak in Punjab are expected to drive demand for vaccines and disease-prevention products in the livestock sector. In the poultry sector, anticipated layer placements are likely to boost growth in the biological, nutritional and anti-infective portfolio.

The business remains focused on sustainable growth through portfolio rationalisation, margin optimisation, and the establishment of a new greenfield medicine manufacturing facility, which is currently underway to expand its local production capabilities and enhance its medicine portfolio.

Chemicals & Agri Sciences Business

Net Turnover (PKR m)



The Net Turnover and Operating Result for the nine-months period under review at PKR 10,229 million and PKR 1,500 million, are lower by 5% and 11% compared to the SPLY, respectively.

During the period under review, the Chemicals and Masterbatches segments experienced an improved demand compared to the SPLY recording volumetric growth of 15% and 20% respectively. However, margins continued to be impacted on account of easing import restrictions amid enhanced competition, appreciation of PKR, pressure on commodity prices and declining consumer purchasing power.

The Agri Sciences Business continued to face challenges during the period owing to temperature volatility affecting crops, non-seasonal rains, market liquidity constraints, shift in farmers

Operating Result (PKR m)



cropping preference and the financial strain on farmers on account of decline in support prices. With low produce prices and high input costs, farmers are less inclined towards spending their limited resources on high crops solutions, mainly pesticides, which dampened sales. Although the provincial government has taken some steps to improve liquidity amongst farmers in the form of access to subsidised loans, its impact will be seen from the Kharif season.

While government measures to stabilise the economy are gradually showing results, improvements in the overall business environment and demand may take time. In the short term, the business will face ongoing challenges in demand and profitability. However, the focus remains on operational excellence and cost optimisation to mitigate these impacts.

10

Future Outlook

According to the International Monetary Fund (IMF), the global economic growth is projected at 3.3% in 2025, reflecting a resilient outlook despite challenges such as supply chain disruptions from the Middle Eastern conflicts, the continuing impact of Russia's war on Ukraine and risk of rising protectionism. Policy rates are now on a downward trajectory, with headline inflation expected to decline from an average of 5.9% in 2024 to 4.3% in 2025.

The recently imposed U.S. tariffs, along with retaliatory measures by China and the ensuing risk of a trade war, are expected to remain a key source of economic uncertainty going forward. As a result, major financial institutions such as Goldman Sachs and JPMorgan have flagged an elevated risk of both U.S. and global recession, with global growth likely to face additional headwinds. The outlook going forward will depend on how the global trade dynamics evolve, policy responses from major economies, and the ability of global supply chains to adapt to the shifting landscape.

Despite these potential risks, Pakistan has made notable progress towards macroeconomic stabilisation, supported by robust private consumption and investment, lower inflation, high remittance inflows and increased credit to the private sector, as reported by the World Bank. The growth rate for FY 2024-25 is projected at 2.6%, and the average inflation rate is expected to decline to 6%. The Staff-Level Agreement under the Extended Fund Facility (EFF) reached in March 2025 would further support recovery. Recent policy rate cuts, driven by improved inflation figures, have provided some relief; however, restoring consumer confidence and achieving robust economic stability will take time.

Building on this progress, the Company is well-positioned to handle future uncertainties due to its strong balance sheet and

diversified portfolio which is aligned with Pakistan's core economy. The Company continues to pursue strategic growth initiatives, optimising capital allocation for both organic and inorganic expansion. The Company conducts regular strategic reviews to assess and develop proactive strategies to mitigate risks. Notwithstanding the above, one such risk affecting industry at large is the proposed import tariff reduction program by the Government of Pakistan, which if not properly thought through could lead to large scale deindustrialization in local value accretive sectors with accompanying job losses.

Looking ahead, the Company will continue to focus on identifying new revenue streams, optimising operating costs, and maximising shareholder returns to ensure a resilient and sustainable future.

Composition of the Board

In line with the requirements of the Listed Companies (Code of Corporate Governance) Regulations, 2019, the Company encourages the representation of Independent and Non-Executive Directors, as well as gender diversity, on its Board.

The current composition of the Board is as follows:

Total number of Directors:

(a) Male: 7(b) Female: 1

Composition:

(i) Independent Directors: 3(ii) Non-Executive Directors: 4(iii) Executive Directors: 1

And som

Asif Jooma Chief Executive

Muhammad Sohail Tabba Chairman

Date: April 22, 2025 Karachi

دائر يكثر زكاجائزه 31 مارچ 2025 کوختم ہونے والی 9 ماہ کی مدت کے لیے۔ان کنسولیڈیٹڈ

فار ماسیو ٹیکلز بزنس کی کار کردگی میں اضافہ ، فائزر یا کستان کمیٹڈاور فائزر گروپ کی دیگر متعلقہ کمپنیوں سے حاصل کر دہاثاثوں کے بلار کاوٹ انضام کی برولت ممکن ہوا، جو کمپنی کے لیے ایک اہم سنگ میل کی حیثیت رکھتا ہے۔ بنیادی کار وباری کار کر دگی،مار جن کی بحالی کی بدولت ممکن ہوئی، جسے پاکستانی دوپے کی قدر میں بہتر میاوراستحکام، کچھ غیر لازم ادویات کی قیتوں میں افراط زرکے حوالے سے ایڈ جسٹمنٹ، سیلز مکس میں بہتر محاود عملی کار کردگی پر مسلسل توجه سے فائڈہ ہوا۔

یولیئسٹر کے کار وبار کی بہتر کار کردگی،مالی سال25-2024 کی پہلی ششہای میں مال بر داری کی بڑھتی ہوئی عالمی قیمتوں کی وجہ سے ہوئی، جس نے در آمد شدہ پی ایس ایف کو مہنگا کر دیا، خصوصی نوعیت کی مصنوعات کی فروخت میں بہتر میاور عملی کار کردگی میں اضافیہ کیا۔ سوڈاایش کے کار وبار پر بڑے شعبوں میں مقامی طلب میں کمی کااثر جاری رہا۔ مزید بر آں، برآمدی فروخت نمایاں طور پر متاثر ہوئی کیونکہ برآمدی قیمتیں کم اورمال بر داری کی قیمتیں زیادہ تھیں، جس کی وجہ سے برآ مدی فروخت اقتصادی طور پر نا قابل عمل ہو گئی۔ کیمیکلزاینڈ ایگری سائنسزاور اینیمل ہیلتھ کے کاروبارنے صارف کی قوت خرید میں کمی کی وجہ سے طلب کے محاذیر چیلنجز کاسامنا کیا۔

6 ستمبر 2024 کو تمپنی نے فائزر پاکستان کمیٹڈ اور فائزر گروپ کی دیگر متعلقہ کمپنیوں کے ساتھا یک اثاثہ خریداری مکمل کی (براہ کرم 1 8مارچ 2025 کو ختم ہونے والی نوماہ کی مدت کے لیے مالی گوشوار وں کانوٹ 5 ملاحظہ کریں)۔اس معاہدے میں ایک مینوفیچر نگ پلانٹ، منتخب ادویات اور متعلقہ ٹریڈمار کس کی خرید وفر وخت شامل تھی(وہ چاہے ٹریڈ مار کس کی براہ راست تفویض کے ذریعے ہویافائزر گروپ کی متعلقہ کمپنیوں سے متعلقہ ٹریڈ مار کس کے استعال کے لیے مستقل لائسنس کے ذریعے)۔

زیر جائزہ نوماہ کی مدت کے لیے منافع بعداز خیس (پی اے ٹی) 8,805 ملین روپے ہے، جو گزشتہ سال کیاسی مدت کے مقابلے میں %11 زیادہ ہے، جس کی بنیاد ی وجہ اعلیٰ آ پر ٹینگ نتائج اور مالیاتی لاگت میں کمی ہے، جو گزشتہ سال کی اسی مدت کے مقابلے میں اوسط پالیسی ریٹ میں 600 بیسس پوائنٹس کی کمی ہے منسوب کی جاسکتی ہے۔ یہ کار کردگی اس حقیقت کے باوجود سامنے آئی کہ بر آمدات پر فیکس کے نظام میں تبدیلی کی وجہ سے مؤثر نیکس کی شرح میں اضافہ ہوا، جس کااطلاق کیم جولائی 2024 سے ہوا۔

ڈائر یکٹر ز 31 مارچ 2025ء کو ختم ہونے والی سہ ماہی اور 9 ماہ کی مدت کے لیے تمپنی کے غیر آڈٹ شدہ مالیاتی گوشوار وں کے ساتھ اپناجائزہ بمسرت پیش کرتے ہیں۔


سہ ماہی کے لیے خالص مجموعی فروخت 29,821 ملین رہی، جو گزشتہ سال کے اس عرصے(SPLY) کے مقابلے میں%4 کم ہے۔فارماسیو فیکلز برنس کی خالص مجموعی فروخت SPLY کے مقابلے میں%62 زیادہ ہے، جبکہ سوڈاایش، یولیکسٹر، اینسیمل ہیلتو اور کیمیکزاینڈا گمری سائنسز کے کاروبار میں طلب میں کمی کی وجہ سے SPLY کے مقابلے میں بالتر تیب%16،%10،10 اور%3 کی کمی داقع ہوئی ہے۔

سہ ماہی کے لیے آپریشنز سے منافع 4,269 ملین روپے ہے جو SPLY کے مقابلے میں 6% کم ہے۔فارماسیو ٹیکلز اور اینٹیمل ہیلتو کے کار وبارنے SPLY کے مقابلے میں بالترتيب%80اور%8 زيادہ آپريٹنگ منافع فراہم کيا، جبکہ ملکی مارکيٹ ميں ست روی کی وجہ سے سوڈاایش، پولیئسٹر اور کیمیکلز اینڈ ایگر می سائنسز کے کاروبار نے بالتر تیب%22، 27%اور%1 کی کمی کاسامنا کیا۔ سوڈاایش کے کار وبار پر خاص طور پر ملکی اور علا قائی قیمتوں میں کمی اور فروخت کے تخمینے سے کم حجم نے اثر ڈالا۔


زیر جائزہ نوماہ کے دورانیے کے لیے خالص مجموعی فروخت 92,093ر ہی،جو SPLY کے مقابلے میں 1% ازیادہ ہے۔فارماسیو خیکز اور یولیئسٹر کے کاروبار میں بالتر تیب%74 اور%5اضافہ ہواہے جبکہ سوڈاایش،اینیمل ہیلتھاور کیمیکازاینڈا یگر می سائنسز کے کاروبار میں بالتر تیب%17%،12% اور%5 کی کمی واقع ہوئی۔

زیر جائزہ نوماہ کے دورانیے کے لیے آپریشنز سے منافع 13,609 ملین روپے ہے جو SPLY کے مقابلے میں 8% زیادہ ہے۔فارماسیو ٹیکٹر اور یو لینسٹر کے کار وبارنے SPLY کے مقابلے میں بالتر تیب%122اور %31 زیادہ آپر ٹینگ منافع فراہم کیا۔ اینیمل ہیلتھ کے کاروبار کی آپریٹنگ کار کردگی تقریباً SPL Yکے مطابق رہی، جبکہ سوڈا ایش اور کیمیکاز ایڈ ایگری سائنسز کے کار وبارنے SPLY کے مقابلے میں بالتر تیپ%15 اور%11 کی کمی کاسامنا کیا۔ زیر جائزہ نوماہ کی مدت کے لیے فی شیئر آمد نی (ای پی ایس) 34.94 ہے، جو گزشتہ سال کی اسی مدت کے مقابلے میں %11 زیادہ ہے۔

اضافہ/(کمی)%	مارچ24 میں مکمل ہونے والے 9 ماہ	مارچ 25 میں کلمل ہونے والے 9 ماہ	(ملین پاکستانیروپ)
1%	91,281	92,093	خالص مجموعى فروخت
5%	19,821	20,889	کل منافع
8%	12,598	13,609	<i>ا</i> یر ملینگ ^م یچه
16%	12,080	14,069	منافع قبل از شيكسس
11%	7,933	8,805	منافع بعداز فيكسس
11%	85.89	95.34	فی حصص آمدنی(پاکستانی روپے)







ز بر جائزہ نوماہ کے دوران، عالمی اجناس کی منڈیاں چین اورام ریکہ میں توقع کے مقالمے میں طلب کی ست بحالی کی وجہ سے چیلنجز کا سامنا کرتی رہیں۔ چین میں طلب کمز وررہی کیو نکہ گھرانوں نے خرچ میں کمی برقرارر کھی،جولاگت میں کمی کے حاریاقدامات کی عکاسی کرتی ہے۔

زیر جائزہ مدت کے دوران، خام تیل کی اوسط قیمت میں گزشتہ سال کے اسی عرصے کے مقابلے میں %9 کی کمی آئی ہے۔ نتیجتاً PXاور PTA کی منڈیوں کو بالتر تیب%15 اور 13% کی کمی کاسامنا کر ناپڑا۔ تاہم، MEG کی منڈی نے کم ہوتے ہوئے ذخائر کے باوجو د مضبوطی کا مظاہر ہ کیااور گزشتہ سال کے اسی عرصے کے مقابلے میں اوسط قیبت میں %10 كالضافيه حاصل كبابه

کیاس کے شعبے میں بہتر دستیابی نے کیاس کی عالمی قیمتوں پر دباؤ بر قرار رکھا، کیونکہ بیہ گزشتہ سال کے اسی عرصے کے مقابلے میں %20 کمی کا شکار ہو گئیں۔مزید یہ کہ مار کیٹ میں درآمد شدہ کیاس کی دستیابی کی وجہ سے مقامی کیاس کی قیمتیں گزشتہ سال کے اسی عرصے کے مقابلے میں %4 کی کمی سے دوجار ہوئیں۔


زیر جائزہ نوماہ کے دوران، خالص مجموعی فروخت میں گزشتہ سال کے اسی عرصے کے مقابل میں 5% کااضافہ ہوا۔ آپریٹنگ منافع میں، جو کہ 1,719 ملین روپے ہے، گزشتہ سال کے اسی عرصے کے مقابلے میں % 31 کااضافیہ ہوا۔

توانائی کی بڑھتی ہو ئی قیمتوں کے باد جود ، جس کی بنیادی وجہ در آمد شدہ RLNG پر زیادہ انحصارے،اس کار وبارنے اپنے آپریٹینگ منافع میں بہتری لانے میں کامیابی حاصل کی۔اس کار کردگی کی بنیاد بر می حد تک خصوصی فائبر کی مختلف اقسام، بشمول، CICLO Repreve اوراینٹی مائکر و بنگن فائبر کی بڑھتی ہوئی فروخت تھی۔ اس کے علاوہ اس ېزنس کې کار کردگې کومالي سال 25-2024 کې پېلې ششماېي ميں مال بر دارې کې بلند عالمي قیتوںنے بھی سہارادیا، جس نے درآ مدات کے مقابلے میں مقامی مارجن کو بہتر بنایا اور کاسٹ مینجمنٹ پر توجہ مرکوز کی۔

مستقبل کے نقطہ نظریے خام تیل کی قیمتوں میں اتار چڑھاؤ کی توقع ہے، جوام پکہ کے جوابی ٹیکس اقدامات کے اثرات کی وجہ سے سے اور فیڈ اسٹاک کی منڈیوں کی جانب سے خام تیل کے رجحانات کی پیروی کیے جانے کی توقع ہے۔ چینی برآ مدات پر ٹیکس کاد باؤچین کو دوسری جگہوں پر توجہ مرکوز کرنے پر مجبور کرے گا، جس کے بنتیج میں پاکستان سمیت خطے میں مزید ڈمینگ ہو سکتی ہے۔ ڈمپ شدہ در آمدات میں مزید اضافہ PSF اور ڈاؤن اسٹریم اسینگ صنعت کے لیےا یک بڑامسابقتی چینجین جائے گا۔ پاکستان کی وزارت تحارت کی ٹیم کی امریکہ کی ٹیکس ٹیم کے ساتھ فعال مشغولیت کی ضرورت ہو گی تاکہ ایک زیادہ معقول ٹیر ف پر بات چت کی جاسکے، جس کے لیے طویل وقت کی ضرورت ہو گی تا کہ صنعت کو ایڈ جسٹ کرنے کاموقع مل سکے۔

14





کرنے کے لیے بلامنافع اور بعض او قات منفی مارجن پر مصنوعات بر آمد کرنے پر مجبور ہوناپڑا۔

خاص طور پر ترکی ہے ڈ میپڈ قیمتوں پر در آمدات نے ملکی مینوفی چر رز کی فروخت پر مزید اثر ڈالا۔ کمپنی قومی ٹیرف کمیشن اور وزارت تحجارت کے سامنے اصلاحی اقد امات کے لیے مناسب نما ئندگی جاری رکھے ہوئے ہے، بصورت دیگر مقامی صنعت کاروں کو ناقابل تلافی نقصان کا سامنا کر ناپڑ سکتا ہے۔

ملکی سطح پر، مجموعی اقتصادی منظر نامہ چیلنجنگ رہا، ملکی مار کیٹ طلب میں کمی کی وجہ سے پوری صلاحیت سے کم پر چلتی رہی۔ نئے آئی ایم ایف پیکج اور افراط زر میں کمی عیسی مثبت پیش رفت کے باوجود اسٹر کچرل اصلاحات اور مالی نظم وضبط کے بغیر پائیدار اقتصادی ترقی کا امکان کم ہے۔

بر آمدات کے محاذیر، بین الا قوامی قیمتیں وافرر سداور کمز ور طلب کی وجہ سے دیاؤ میں ہیں، جبکہ چینی پر وڈیو سرزنے پلانٹ آپر ٹینگ ریٹس کو بر قرار رکھنے کے لیے منفی مار جن پر بر آمدات جاری رکھی ہیں۔ عالمی سوڈاایش مار کیٹ دباؤمیں رہی، بنیادی طور پر کمز ور طلب اور زیادہ رسد کی صور تحال کی وجہ سے، خاص طور پرچین میں۔ چینی پر وڈیو سر زنے کلیدی شعبوں میں مند ی کی شکار طلب کے تناظر میں آپر ٹینگ ریٹس کو بر قرار رکھنے کے لیے منفی مار جن پر بر آمدات جاری رکھیں، جس میں تعمیر اتی سر گرمیوں میں ست روکی اور سولر پینلز پر عاکد غیکسوں کے اثرات بھی شامل ہیں۔

زیر جائزہ نوماہ کے دوران سوڈاایش بزنس نے 30,063 ملین روپے کی خالص مجموعی فروخت اور 6,180 ملین روپے کا آپریٹنگ منافع حاصل کیا، جو کہ SPLY سے بالتر تیب 17% اور 15% کم ہیں۔ یہ اس کے باوجود ہوا کہ گزشتہ سال 560,000 ٹن کی اضافی پید اوار کی صلاحیت کوروبہ عمل لایا گیا تھا۔

زیر جائزہ مدت کے دوران ملکی سوڈاایش مار کیٹ دباؤیٹ رہی۔ ملکی فروخت SPLY کے مقابلے میں %90 کم ہوئی، جو کمزور طلب کی وجہ سے ہے جس کا سبب اہم شعبوں میں قوت خرید میں کمی ہے۔ برآ مدات SPLY کے مقابلے میں %42 کم رہیں کیو نکہ بین الا قوامی مارکیٹ میں ست روی کی وجہ سے قیمتیں کم رہیں، جس کے نتیج میں مار جن اور تجم میں کمی آئی۔ مزید برآں، آپر ٹینگ ریٹس کو بر قرار رکھنے کی خاطر ترکی اور چین کی پیشکشوں کے ساتھ مقابلہ

فارماسيو شيكزيزنس



فارماسیوٹیکل بزنس کی خالص مجموعی فروخت نوماہ کی زیر جائزہ مدت میں 15,536 ملین روپے رہی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں%74 زیادہ ہے اور آپر ٹینگ منافع 3,427 ملین روپے ہے جو گزشتہ سال کے اسی عرصے کے مقابلے میں %122 زیادہ ہے۔

زیر جائزہ نوماہ کے دوران، فارماسیو ٹیکل بزنس کے لیے ایک بڑی کامیا بی Pfizer کی کمپنیوں سے حاصل کر دہ پورٹ فولیو کا بلار کاوٹ انتخام تھا، جو تر تی کے لیے ایک اہم سنگ میل کی حیثیت رکھتا ہے۔ اس حصول نے مصنوعات کے موجودہ پورٹ فولیو کو مزید بیش قدر بنایا، کار وبار کی مارکیٹ تک رسائی کو بڑھا یا اور سے کلید کی معالجاتی شعبوں میں مصنوعات تک پہتر رسائی اور بڑھتی ہوئی عملی ہم آہ ہتگی کے ذریعے مسلسل ترقی کو فروغ دینے میں مدد دے گا۔ مزید بر آل، غیر لاز مادویات کی قیتوں میں ایڈ جسٹمنٹ نے مارکیٹ کی حرکیات کو قیمتوں کو ایڈ جسٹ کرنے کی اجازت دی، جس سے تیارکنند گان کو بڑھتی ہوئی لاگت سے نمٹنے کے لیے زیادہ کچل ملی جا ہم، اس شعبہ کو زندگی بچانے والی ضرور کی ادویات کی اقتصاد ک




پائیداری کے حوالے سے چیلنجز کاسامناہے،جو بڑھتی ہوئی لاگت اور قیمتوں کی ناکافی ایڈ جسٹمنٹ کی وجہ سے ہیں۔

چیلنجز کے باوجود، LCI کا فارماسیو شیکل بزنس نئی مصنوعات متعارف کروا کے لاگت میں اضافے کو کم کرنے میں کا میاب رہا ہے تا کہ مار کیٹ کی اب تک پور کی نہ ہونے والی طلب کو پور اکیا جاسکے، پیداوار کی کار کر دگی کو بڑھا یا جاسکے اور ور کنگ کیپیٹل کو بہتر بنایا جاسکے۔

مستقبل کے نقطہ نگاہ سے فارماسیو ٹیکل بزنس،مار کیٹ میں اپنی متحکم موجود گیا در آگ دیکھنے کے طریقہ کار کافائدہ اٹھاتے ہوئے اپنی ترقی کی رفتار کو بر قرار رکھنے کے لیے پور ی طرح تیار ہے، تاہم، ضر ور کی ادویات کے لیے ایک زیادہ پائیدار ریگولیٹر کی فریم ورک کی فور م ضر ورت باقی ہے۔ بر آمدات پر زیادہ ٹیکس اور ضر ور ی خام مال پر ڈیو ٹیز عائد کرنے سے لاگت کے دباؤ میں اضافہ ہوا ہے۔ ان ضر ور کی افتطہ نظر انتہا تی اہم ہے۔


انيمل ہيلتھ بزنس



زیر جائزہ نوماہ کی مدت میں اینیمل ہیلتھ بزنس کی خالص مجموعی فروخت 4,498 ملین روپے رہی جو کہ گزشتہ سال کے اسی عرصے کے مقابلے میں 12% کم ہے اور آپر ٹینگ منافع 783 ملین روپے ہے جو گزشتہ سال کے اسی عرصے کے مطابق ہے۔

پاکستان میں اینیمل ہیلتھ کی صنعت ایک ترقی پذیر کار وبار کی ماحول کے مطابق ڈھل رہی ہے، جس میں فیڈ پر سیلز ٹیکس کے نفاذ کی وجہ سے فار مینجہنٹ کی بڑھتی ہو ئی لاگت، مکئی کی قیمتوں میں اضافہ ، نوزائیدہ چوزوں کی زیادہ قیمتیں اور توانائی کی بڑھتی ہو ئی لاگت مویشیوں کے لیے ضروری خوراک اور ادویات میں کسانوں کی سرمایہ کار کی کی صلاحیت کو محد ود کر رہی ہیں۔

لائیواسٹاک سیکٹر میں ایٹی بایو تکس، کیڑے ماراد ویات اور تولیدی حل کی طلب بلندر ہی۔ ڈیری فار مرز دود دو دینے کے عروج کے عرصے میں مؤثر گلہ بانی کو ترجیح دے رہے ہیں تا کہ دود دھ کی پید اوار اور مویشیوں کی تولید کی اہلیت کو بہتر بنایاجا سکے مزید بر آل، بودائن (bovine) جینیٹک پورٹ فولیو کی بڑھتی ہوئی طلب اس شیعے میں گلہ کے معیار اور پید اواریت کو بڑھانے پر زور دیتی ہے۔ حکومت کی جانب سے پنجاب میں مولیتی کارڈ جیسے اقد امات نے کسانوں کی مدد کی ہے، جس سے انہیں ضر وری فیڈ مار کیٹ پر اثر انداز ہو تا میں آسانی ہوئی ہے۔ تاہم، فیڈ کی اشیاء پر سیلز ٹیکس مولیتیوں کی فیڈ مار کیٹ پر اثر انداز ہو تا




پولٹری کے شعبے میں چکن کی قیمتوں بڑھی ہیں کیونکہ نوزائیدہ چوزوں کی محدود دستیابی کی وجہ سے سیز ٹل طلب میں اضافہ ہوا۔ وائرل و بائیں، خاص طور پرایوین انفلو ئنزا، فلو ویسین کی طلب کو بڑھار ہی ہیں، جبکہ سیکنڈر ی بیٹ پیریل انفیکشنز نے اینٹی بایو ^{عک}س کی طلب میں اضافہ کیاہے، جس سے کاروبار کو بایولو جیکل اوراینٹی بایو ځک دونوں شعبوں میں اپنامار کیٹ شیئر بڑھانے میں مدد ملی ہے۔

پولٹر میاورلا ئیواسٹاک مارکیٹوں میں گزشتہ سال کے ای عرصے کے مقابلے میں بالترتیب %25اور%20 کی کمی کے باوجود کاروبارنے بہتر مصنوعات سازی، کار کردگی میں اضافہ اورلاگت پر کنڑول کے ذریعے کچک دکھائی۔ مستغبل کے نقطہ نگاہ ہے، پنجاب میں خراب موسمی حالات اور فٹ اینڈماؤتھ وہا کے باعث توقع ہے کہ مویشیوں کے شعبے میں ویسین اور بیاری کی روک تھام کی مصنوعات کی طلب بڑھے گی۔ پولٹری کے شعبے میں، متوقع لیئر پلیں منٹس کی برولت بایولوجیکل، نیوٹریشنل اورا پنجی انفیکٹو پورٹ فولیو میں اضاف کی توقع ہے۔

اینیمل ہیلتھ بزنس پائیدار ترقی پر توجہ مر کوزر کھتا ہے، جس میں پورٹ فولیو کی محقولیت، مار جن کی بہتر می اور ایک نٹی گرین فیلڈ دوا کی پید اوار می سہولت کا قیام شامل ہے، بیا اقدامات پید اوار کی مقامی صلاحیت کو بڑھانے اور اپنے میڈیسن پورٹ فولیو کو بہتر بنانے کے لیے کیے جارہے ہیں۔

کیمیکزاینڈا گگری سائنسز بزنس



میں لیکویڈیٹی کی رکاد ٹیں، کسانوں کی فصلوں کی ترجیجات میں تبدیلی اور سپورٹ پر السز میں کی کی وجہ سے کسانوں پر مالی دباؤشا مل ہیں۔ کم پید اداری قیتوں اور زیادہ لاگت کے ساتھ، کسان اپنے محد ود وسائل کو فصلوں کے مسائل کے حل، خاص طور پر کیڑے مارادویات پر خرچ کرنے میں کم دلچیپی رکھتے ہیں، جس سے فروخت میں کمی آئی۔ اگرچہ صوبائی حکومت نے کسانوں کے لیے سبیڈی والے قرضوں تک رسائی کی صورت میں کیکویڈیٹی کو بہتر بنانے کے لیے پچھ اقد امات کیے ہیں، جن کا اثر خریف کے موسم سے دیکھا جائے گا۔

حکومت کے اقدامات معیشت کو منتخکم کرنے کے لیے بتدر بنج نتائج د کھارہے ہیں، تاہم مجموعی کار وبار کی ماحول اور طلب میں بہتر کی آنے میں وقت لگ سکتا ہے۔ مختصر مدت میں، سیہ کار وبار طلب اور منافع میں جاری چیلنجز کا سامنا کرے گا۔ تاہم، توجہ عملی بہترین کار کر دگی اور لاگت کی بہتری پر مرکوزہے تاکہ ان اثرات کو کم کیا جائے۔ زیر جائزہ نوماہ کی مدت کے دوران خالص مجموعی فروخت اور آپر ٹینگ منافع بالتر تیب 10,229 ملین روپے اور 1,500 ملین روپے رہا، جو کہ گزشتہ سال کے اسی عرصے کے مقابلے میں%5اور%11 کم ہے۔

زیر جائزہ مدت کے دوران، کیمیکلزاور ماسٹر بیچر نے شعبوں میں گزشتہ سال کے اسی عرصے کے مقابلے میں بہتر طلب کا تجربہ ہوااور جم کے لحاظ سے بالتر تیب%15 اور%20 اضافہ ریکارڈ کیا گیا۔ تاہم ،مارجن پر در آمدی پابندیوں میں نرمی، بڑھتی ہوئی مقابلہ آرائی، روپے کی قدر میں اضافہ ،اجناس کی قیمتوں پر د باؤاور صار فین کی قوت خرید میں کمی کی وجہ سے اثرات مرتب ہوتے رہے۔

ایگری سائنسز کاکار وباراس مدت کے دوران چیلنجز کا سامنا کر تار ہا، جس کی وجو ہات میں درجہ حرارت کے عدم استحکام کی وجہ سے فصلول کامتاثر ہونا، غیر موسمی بارشیں ،مار کیٹ

مستقبل كامنظرنامه

کرنے میں بہتر کالا کراسٹر یتجب ترقی کے لیے اقدامات جاری کھے ہوئے ہے۔ کمپنی با قاعد گی سے اسٹر یتجب جائز سے لیتی ہے تا کہ خطرات کو کم کرنے کے لیے فعال حکمت عملیوں کا اندازہ لگا یا جاسکے اور انہیں ترقی دی جاسکے اوپر بیان کردہ معاملات کے ساتھ ایک ایسا خطرہ جو صنعت کو بڑے بیانے پر متاثر کررہاہے ،وہ پاکستانی حکومت کی جانب سے تجویز کردہ در آمدی شیک س ملی کی کاپر و گرام ہے، جس پر اگر صحیح طور پر نہ سوچا گیا تو یہ متامی قیمت بڑھانے والے شعبوں میں بڑے پیانے پر صنعتی زوال کا باعث بن سکتا ہے، جس کے ساتھ ملاز متوں کا نقصان بھی ہو گا۔

مستقتبل کی جانب دیکھتے ہوئے، کمپنی آمدنی کے نئے ذرائع کی تلاش، آپریٹنگ لاگت میں بہتر میاور شیئر ہولڈرز کے منافع کوزیادہ سے زیادہ کرنے پر توجہ مر کوزر کھے گی تا کہ ایک مضبوط اور پائیدار مستقتبل کویقینی بنایا جا سکے۔

بورڈی تفکیل ^{لسٹر} کمپنیز(کوڈ آف کار پوریٹ گور ننس)ر یکولیشنز 2019 کے تقاضوں کے مطابق سمپنی اپنے بورڈ میں آزادادر نان ایگزیکٹوڈائر یکٹرز کی نما ئندگی کے ساتھ ساتھ صنفی تنوع کی حوصلہ افنرائی کرتی ہے۔

> **بورڈ کی موجودہ ٹھکیل درج ذیل ہے** ڈائر کیٹر زکی کل تعداد (الف)مر د 7 (ب)خواتین 1

> > ساخت (i)آزاد ڈائریگرز3 (ii)نان ایگزیکٹوڈائریگرز4 (iii)ایگزیکٹوڈائریگرز1

بین الا قوامی مالیاتی فنڈ (IMF) کے مطابق 2025 میں عالمی اقتصادی ترقی کی شرح%3.3 متوقع ہے، جو مشرق وسطی کے تنازعات کے باعث سپلائی چین میں خلل، روس یو کرین جنگ کے جاری اثرات اور بڑھتی ہوئی تحفظ پیندی کے خطر ہے جیسے چیلنجز کے باوجودا یک متحکم منظر نامہ کی عکامی کرتی ہے۔ پالیسی ریٹس کارخ اب نیچ کی طرف ہےاور توقع ہے کہ ہیڈلائن افر اط زر 2024 کی اوسط%2.5 سے کم ہو کر 2025 میں %4.3 ک

حال ہی میں علد کر دوامر کی ٹیرف کے ، چین کی جانب سے جوابی اقد امات اور تجارتی جنگ کے خطر ے کے ساتھ ، مستقبل میں اقتصادی بے یقینی کا ایک اہم ذریعہ بند بنے کاا مکان ہے۔ نتیجتاً، بڑے الیاتی ادارے جیسے گولڈ مین ساکس اور جے پی مور گن نے امریکی اور عالمی کساد بازاری کے بلند خطر ہے کی نشاند ہی کی ہے ، جبکہ عالمی ترقی کواصافی مشکلات کا سامنا کر ناپڑ سکتا ہے۔ مستقبل کا منظر نامہ، عالمی تجارتی حرکیات کس طرح ترقی کر قی ہیں ، بڑی معیشتوں کی جانب سے جوابی پالیسیوں اور عالمی سپلائی چین کے تبدیلی کے منظر نامے کے مطابق ڈھلنے کی صلاحت پر منحصر ہو گا۔

ان ممکنہ خطرات کے باوجود پاکستان نے میکر واقتصادی استحکام کی جانب قابل ذکر پیشر فت کی ہے، جس کی معاونت مضبوط نجی کھپت اور سرمایہ کار کی، کم افر اط زر، زیادہ تر سیلات زر اور نجی شعبے کے لیے بڑھتے ہوئے کریڈٹ کی صورت میں ہوئی ہے، جیسا کہ عالمی بینک نے رپورٹ کیا ہے۔ مالی سال 25-2024 کے لیے ترقی کی شرح% 2.6 متوقع ہے اور اوسط افر اط زر کی شرح% کا تک کم ہونے کی توقع ہے۔ مارچ 2025 میں طے پانے والا اسٹاف لیول معاہدہ توسیعی فنڈ کی سہولت (EFF) کے تحت بحالی کی مزید معاونت کرے گا۔ پالیسی ریٹ میں صالیہ کی، جو بہتر افر اط زرکے اعداد و شار کی وجہ ہے ہوئی ہے، پچھ راحت فراہم کرتی ہے، تاہم صار فین کے اعتماد کی بحالی اور مضبوط اقتصادی استحکام حاصل کرنے میں وقت کھے گا۔

اس پیشر فت پر بنیادر کھتے ہوئے، کمپنی مستقبل کی غیر یقینی صور تحال کاسامنا کرنے کے لیے اچھی طرح سے تیار ہے کیونکہ اس کی بیکنس شیٹ مضبوط ہے اور پورٹ فولیو پاکستان کی بنیاد می معیشت کے ساتھ ہم آ ہنگ ہے۔ کمپنی نامیاتی اور غیر نامیاتی دونوں طرح کی تو سیچ کے لیے سرمایہ مختص

محرسهيل شا چيئر مين

تاريخ:22 اپريل 2025 كراچي

Art Jours

آصف جمعه چیف ایگزیکٹو

Unconsolidated Condensed Interim Statement of Financial Position

As at March 31, 2025

	Note	March 31, 2025 (Unaudited)	June 30, 2024 (Audited)
ASSETS		(PKR in	<u>, ,</u>
		,	,
Non-current assets Property, plant and equipment	6	38,104,502	29,766,513
Intangible assets	7	2,979,001	1,682,954
Right-of-use assets	I	268,042	182,457
		41,351,545	31,631,924
Long-term investments	8	2,412,491	2,412,491
Long-term loans	-	847,112	803,868
Long-term deposits and other assets		986,814	287,883
		4,246,417	3,504,242
		45,597,962	35,136,166
Current assets			
Stores, spares and consumables		4,889,511	5,919,026
Stock-in-trade	9	18,445,453	15,395,391
Trade debts	10	5,691,209	5,575,305
Loans and advances		1,396,946	1,028,988
Short-term deposits and prepayments		748,651	1,051,790
Other receivables	11	1,393,907	2,209,662
Short-term investments	12	18,740,717	15,688,484
Cash and bank balances		602,375	1,560,922
T (1)		51,908,769	48,429,568
Total assets	:	97,506,731	83,565,734
EQUITY AND LIABILITIES Share capital and reserves Authorised capital			
1,500,000,000 (June 30, 2024: 1,500,000,000) ordinary shares of PKR 10 each	:	15,000,000	15,000,000
Issued, subscribed and paid-up capital			
92,359,050 (June 30, 2024: 92,359,050) ordinary shares of PKR 10 each		923,591	923,591
Capital reserves		18,309,643	18,309,643
Revenue reserve - unappropriated profit		26,960,076	24,342,772
Total equity		46,193,310	43,576,006
Non-current liabilities		444.057	442.004
Staff retirement benefits	13	114,657 10,315,083	113,984 3,986,348
Long-term loans Lease liabilities	15	181,325	157,478
Deferred tax liability - net	14	2,189,697	2,117,931
Deferred income - government grant	15	521,874	658,955
	10	13,322,636	7,034,696
Current liabilities		,,	.,
Trade and other payables		17,190,623	14,878,140
Accrued mark-up		775,713	576,227
Short-term financing	16	13,704,364	11,734,504
Current portion of long-term loans	13	1,054,484	909,446
Current portion of lease liabilities		74,058	38,547
Current portion of deferred income - government grant	15	187,136	204,473
Taxation - net		4,846,525	4,476,868
Unclaimed dividend		157,882	136,827
		37,990,785	32,955,032
Total equity and liabilities	:	97,506,731	83,565,734
Contingencies and Commitments	17		

The annexed notes from 1 to 27 form an integral part of these unconsolidated condensed interim financial statements.

Muhammad Sohail Tabba

Chairman / Director

Acr Jon

Asif Jooma Chief Executive

Atif Aboobukar Chief Financial Officer

Report for the Nine Months Ended March 31, 2025

Unconsolidated Condensed Interim Statement of Profit or Loss (Unaudited) For the Three Months and Nine Months Period Ended March 31, 2025

	Note	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			(PKR i	n '000)	
Net turnover	18	29,820,809	92,093,088	31,058,842	91,280,824
Cost of sales	18 & 19		(71,204,288)	(24,044,104)	(71,459,521)
Gross profit		6,690,497	20,888,800	7,014,738	19,821,303
Selling and distribution expenses	18	(1,814,706)	(5,515,984)	(1,854,785)	(5,361,286)
Administration and general expenses	18	(606,608)	(1,763,571)	(640,161)	(1,861,671)
Operating result	18	4,269,183	13,609,245	4,519,792	12,598,346
Finance costs		(454,476)	(1,754,954)	(744,693)	(2,732,755)
Exchange (loss) / gain		(18,612)	(29,134)	9,023	131,595
Workers' profit participation fund		(113,774)	(375,709)	(120,714)	(325,118)
Workers' welfare fund		(80,348)	(267,643)	(70,170)	(186,370)
Other charges		(7,299)	(98,445)	(41,907)	(88,394)
		(674,509)	(2,525,885)	(968,461)	(3,201,042)
Gain on bargain purchase	5	-	172,183	-	-
Other income	20	536,323	2,813,358	876,690	2,682,964
Profit before final taxes and income tax		4,130,997	14,068,901	4,428,021	12,080,268
Taxation - Final taxes		(121)	(12,657)	(207,943)	(623,418)
Profit before income tax		4,130,876	14,056,244	4,220,078	11,456,850
Taxation - Income tax					
Current		(1,540,874)	(5,179,117)	(1,392,365)	(3,764,986)
Deferred		(2,974)	(71,766)	65,614	241,293
		(1,543,848)	(5,250,883)	(1,326,751)	(3,523,693)
Profit for the period		2,587,028	8,805,361	2,893,327	7,933,157
			(Pł	(R)	
Basic and diluted earnings per share	21	28.01	95.34	31.33	85.89

The annexed notes from 1 to 27 form an integral part of these unconsolidated condensed interim financial statements.

Muhammad Sohail Tabba Chairman / Director

Ach Jon

Asif Jooma Chief Executive

Atif Aboobukar Chief Financial Officer

Unconsolidated Condensed Interim Statement of Comprehensive Income (Unaudited) For the Three Months and Nine Months Period Ended March 31, 2025

	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
		(PKR	in '000)	
Profit for the period	2,587,028	8,805,361	2,893,327	7,933,157
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	2,587,028	8,805,361	2,893,327	7,933,157

The annexed notes from 1 to 27 form an integral part of these unconsolidated condensed interim financial statements.



Acr Jon

Asif Jooma Chief Executive



Atif Aboobukar Chief Financial Officer

Unconsolidated Condensed Interim Statement of Changes in Equity For the Nine Months Period Ended March 31, 2025

	Issued, subscribed and paid-up capital	Capital reserves	Revenue reserve - unappropriated profit	Total
		(PKR	in '000)	
Balance as at July 1, 2023 (Audited)	923,591	309,643	36,597,410	37,830,644
Profit for the period Other comprehensive income for the period - net of tax	-	-	7,933,157	7,933,157 -
Total comprehensive income for the period	-	-	7,933,157	7,933,157
Transaction with owners: Final dividend for the year ended June 30, 2023 @ PKR 33 per share	-	-	(3,047,849)	(3,047,849)
Interim dividend for the year ended June 30, 2024 @ PKR 27 per share	-	-	(2,493,695)	(2,493,695)
Balance as at March 31, 2024 (Unaudited)	923,591	309,643	38,989,023	40,222,257
Transfer to capital reserves	-	18,000,000	(18,000,000)	-
Profit for the period	-	-	3,207,061	3,207,061
Other comprehensive income for the period - net of tax Total comprehensive income for the period	<u> </u>	-	146,688 3,353,749	146,688 3,353,749
				· · ·
Balance as at June 30, 2024 (Audited)	923,591	18,309,643	24,342,772	43,576,006
Profit for the period	-	-	8,805,361	8,805,361
Other comprehensive income for the period - net of tax Total comprehensive income for the period	<u> </u>	-	8,805,361	 8,805,361
	-	-	0,000,001	0,000,001
Transaction with owners:				
Final dividend for the year ended June 30, 2024 @ PKR 33 per share	-	-	(3,047,849)	(3,047,849)
Interim dividend for the year ended June 30, 2025 @ PKR 34 per share	-	-	(3,140,208)	(3,140,208)
Balance as at March 31, 2025 (Unaudited)	923,591	18,309,643	26,960,076	46,193,310

The annexed notes from 1 to 27 form an integral part of these unconsolidated condensed interim financial statements.

Muhammad Sohail Tabba Chairman / Director

Acr Jon

Asif Jooma Chief Executive

Atif Aboobukar Chief Financial Officer

22

Unconsolidated Condensed Interim Statement of Cash Flows (Unaudited) For the Nine Months Period Ended March 31, 2025

	Note	March 31, 2025	March 31, 2024
	-	(PKR in	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	22	19,448,725	21,532,764
Payments for :			
Non-management staff gratuity and eligible retired employees'			
medical scheme		(32,063)	(23,760)
Staff retirement benefit plans		(57,308)	(47,868)
Income taxes and final taxes		(4,822,117)	(2,983,051)
Interest	-	(1,359,602)	(2,768,274)
Net cash generated from operating activities		13,177,635	15,709,811
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure]	(7,500,192)	(3,707,781)
Payment for acquisition of business	5	(6,311,649)	-
Proceeds from disposal of operating fixed assets		290,910	17,532
Interest income received		179,730	440,059
Short-term investments made		(265,000)	-
Income received on short-term investments	l	291,616	2,012,976
Net cash used in investing activities		(13,314,585)	(1,237,214)
CASH FLOWS FROM FINANCING ACTIVITIES			
Long-term loans obtained	[7,140,551	669,913
Long-term loans repaid		(821,196)	(1,027,411)
Export refinance facility repaid		(117,578)	(62,000)
Payment of lease liabilities		(156,577)	(84,359)
Dividends paid	L	(6,167,002)	(5,527,905)
Net cash generated used in financing activities		(121,802)	(6,031,762)
Net (decrease) / increase in cash and cash equivalents	-	(258,752)	8,440,835
Cash and cash equivalents at the beginning of the period		7,905,480	453,842
Cash and cash equivalents at the end of the period	-	7,646,728	8,894,677
Cash and cash equivalents at the end of the period comprise of:			
Cash and bank balances		602,375	1,175,860
Short term investments	12	18,348,717	14,385,917
Short-term running financing	16	(11,304,364)	(6,667,100)
	-	7,646,728	8,894,677

The annexed notes from 1 to 27 form an integral part of these unconsolidated condensed interim financial statements.

Muhammad Sohail Tabba Chairman / Director

Acr in

Asif Jooma Chief Executive

Atif Aboobukar Chief Financial Officer

For the Nine Months Period Ended March 31, 2025

1. STATUS AND NATURE OF BUSINESS

- 1.1 Lucky Core Industries Limited (the Company) was incorporated in Pakistan under the repealed Companies Ordinance, 1984 (now Companies Act, 2017) (the Act) and is listed on the Pakistan Stock Exchange Limited. The Company is engaged in the manufacturing of polyester staple fibre, POY chips, soda ash, specialty chemicals, sodium bicarbonate and polyurethanes; marketing of seeds, toll manufactured and imported pharmaceuticals and animal health products; merchanting of general chemicals and manufacturing of masterbatch. It also acts as an indenting agent and toll manufacturer. The Company's registered office is situated at 5 West Wharf, Karachi.
- **1.2** The Company is a subsidiary of Lucky Cement Limited (the Holding Company). Lucky Core PowerGen Limited, Lucky TG (Private) Limited and Lucky Core Venture (Private) Limited are the subsidiaries of the Company.
- **1.3** These are the separate unconsolidated condensed interim financial statements of the Company in which investments in subsidiaries and associate are stated at cost less impairment losses, if any.

2. STATEMENT OF COMPLIANCE

- 2.1 These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 'Interim Financial Reporting' (IAS 34), issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 (the Act) and provisions of and directives issued under the Act. Where the provisions of and directives issued under the Act differ with the requirement of IAS 34, the provisions of and directives issued under the Act have been followed.
- **2.2** These unconsolidated condensed interim financial statements are unaudited and are being submitted to the shareholders as required under section 237 of the Act. These unconsolidated condensed interim financial statements do not include all the information and disclosures required in the annual audited unconsolidated financial statements, and should be read in conjunction with the annual audited unconsolidated financial statements of the Company for the year ended June 30, 2024.

3. MATERIAL ACCOUNTING POLICY INFORMATION

- **3.1** The material accounting policies applied in preparation of these unconsolidated condensed interim financial statements are consistent with those followed in the preparation of the Company's annual audited unconsolidated financial statements for the year ended June 30, 2024.
- **3.2** Taxes on income in the interim periods are accrued using the tax rate that would be applicable to the expected total annual profit or loss.

3.3 NEW STANDARDS, AMENDMENTS TO ACCOUNTING AND REPORTING STANDARDS AND NEW INTERPRETATIONS

3.3.1 Amendments and interpretations to accounting and reporting standards that are effective in the current period

There are certain new amendments and interpretations to the accounting and reporting standards which are mandatory for the Company during the current period. However, these do not have any significant impact on the Company's financial statements and therefore are not disclosed in these unconsolidated condensed interim financial statements.

3.3.2 Standards, amendments and interpretations to accounting and reporting standards that are not yet effective

There are certain new and amended standards, interpretations and amendments that are mandatory for the Company's accounting periods beginning on or after July 1, 2025 but are considered not to be relevant or will not have any significant effect on the Company's operations and therefore are not disclosed in these unconsolidated condensed interim financial statements except for the following:

- The new standard - IFRS 18 'Presentation and Disclosure in Financial Statements' (IFRS 18) (published in April 2024 with applicability date of January 1, 2027 by IASB. IFRS 18 when adopted and applicable shall impact the presentation of 'Statement of Profit or Loss' with certain additional disclosures in the financial statements;

24

- The new standards - IFRS S1 'General Requirements for Disclosure of Sustainability-related Financial Information' (IFRS S1) (published in June 2023) and IFRS S2 'Climate-related Disclosures' (IFRS S2) (published in June 2023) with applicability dates of July 1, 2025 by the Securities and Exchange Commission of Pakistan. IFRS S1 and IFRS S2 when adopted and applicable shall require disclose of information about sustainability-related risks and opportunities, respectively; and

- Amendments to IFRS 9 'Financial Instruments' which clarify the date of recognition and derecognition of a financial asset or financial liability including settlement of liabilities through banking instruments and channels including electronic transfers. The amendment when applied may impact the timing of recognition and derecognition of financial liabilities.

The management is in the process of assessing the impacts of the new standards and amendments on the financial statements of the Company.

4. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS

Preparation of the unconsolidated condensed interim financial statements in conformity with the accounting and reporting standards as applicable in Pakistan requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities and incomes and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to estimates are recognised prospectively. In preparing these unconsolidated condensed interim financial statements, the significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the unconsolidated financial statements as at and for the year ended June 30, 2024.

5. BUSINESS ACQUISITION

5.1 In line with the Company's growth aspirations and strategic priorities, during the period the Company acquired a manufacturing facility, selected pharmaceutical products, brands and associated trademarks of Pfizer Pakistan Limited, for a total consideration of PKR 5,000 million. In addition to this the Company also acquired relevant working capital along with inventory for a consideration of PKR 2,437 million out of which PKR 1,125 million relates to deferred consideration which is payable after one year from the acquisition date. The transaction was successfully completed on September 6, 2024 (acquisition date).

As per the requirements of International Financial Reporting Standard 3 – "Business Combinations" (IFRS 3), all identifiable assets acquired and liabilities assumed in business combination are required to be recognised at acquisition date at fair value in the acquirer's statement of financial position. IFRS 3 also allows an acquirer to disclose provisional values when the initial accounting for a business combination is incomplete at the end of the reporting period, which is required to be finalised within the period of one year from the acquisition date.

The Company has recorded the identifiable assets at provisional values, as allowed under IFRS 3, because the necessary valuations and calculations are not finalised as at the reporting date. Any adjustment in the provisional values of identifiable assets will be adjusted in the financial statements of the Company retrospectively from the acquisition date.

5.2 Details of the provisional fair values of the assets acquired are as follows:

	Fair value recognised on
	(PKR in '000)
Indicative value of tangible assets:	
Leasehold land	1,500,800
Building on leasehold land	385,013
Plant, machinery and equipment	1,728,549
Vehicles - net	115,255
Total non-current assets	3,729,617
Stores and spares	153,519
	3,883,136
Indicative value of intangible assets:	
Brands	1,289,047
	5,172,183
Working capital including inventory	2,436,970
Total assets	7,609,153

Report for the Nine Months Ended March 31, 2025

Details of the carrying values of the net assets acquired, purchase consideration and gain on bargain purchase are as 5.3 follows:

	September 06, 2024
	(PKR in '000)
Fair value of net assets acquired	5,172,183
Purchase consideration - paid in cash	(5,000,000)
Gain on bargain purchase	172,183

5.4 Net turnover and operating profit from the acquired business during the period ended March 31, 2025 are as follows:

	(PKR in '000)
Net turnover	5,152,767
Operating profit	1,133,974

The aforementioned results have been reported under the Pharma segment of the Company based on the accounting policies of the Company as disclosed in the unconsolidated annual financial statements for the year ended June 30, 2024.

6.	PROPERTY, PLANT AND EQUIPMENT	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) 1 '000)
	Operating fixed assets - at net book value Capital work-in-progress - at cost Total property, plant and equipment	6.3	26,335,999 11,768,503 38,104,502	24,280,117 5,486,396 29,766,513
6.1	Following is the movement in property, plant and equipment during the period	/ year:		
	Operating fixed assets (WDV) - opening balance Add: Additions / transfers during the period / year	6.2	24,280,117 1,200,367	24,673,221 2,937,422
	Add: Business acquisition during the period / year	5.2	3,729,617	
	Less: Disposals during the period / year (WDV) Less: Depreciation charge for the period / year Operating fixed assets (WDV) - closing balance	6.2	29,210,101 (199,438) <u>(2,674,664)</u> 26,335,999	27,610,643 (19,695) (3,310,831) 24,280,117
	Add: Capital work-in-progress	6.3	11,768,503 38,104,502	5,486,396 29,766,513

6.2 Following are the details of operating fixed assets that have been added / transferred and disposed off during the period / year:

	Additions	Additions / Transfers		sals at k value
	For the period ended March 31, 2025 (Unaudited)	For the year ended June 30, 2024 (Audited)	For the period ended March 31, 2025 (Unaudited)	For the year ended June 30, 2024 (Audited)
		(PKR i	n '000)	
Leasehold land	63,254	-	-	-
Lime beds on freehold land	-	265,112	-	-
Buildings on freehold land	93,311	103,406	-	-
Buildings on leasehold land	41,121	529,996	143	1,502
Plant and machinery	838,691	1,784,866	85,064	14,827
Rolling stock and vehicles	-	20,235	110,665	-
Furniture and equipment	163,990	233,806	3,566	3,365
	1,200,367	2,937,422	199,438	19,695

6.3 Following is the movement in capital work-in-progress during the period / year:

		Pe	eriod ended March	31, 2025 (Unaudited)	
	Civil works and buildings	Plant and machinery	Furniture and equipment	Advances to suppliers / contractors	Designing, consultancy and engineering fee	Total
			(PKR ir	n '000)		
Opening balance	377,622	1,817,208	611,430	1,999,814	680,322	5,486,396
Additions during the period	1,045,872	3,798,516	491,586	1,489,689	554,644	7,380,307
Transferred to operating fixed						
assets during the period	(156,743)	(745,501)	(141,134)	(30,165)	(24,657)	(1,098,200)
Transfers between categories	100,829	2,645,478	2,081	(2,748,912)	524	-
Closing balance - note 6.3.1	1,367,580	7,515,701	963,963	710,426	1,210,833	11,768,503
			Year ended June 3	30, 2024 (Audited)		
	Civil works and buildings	Plant and machinery	Furniture and equipment	Advances to suppliers / contractors	Designing, consultancy and engineering fee	Total
			(PKR ii	n '000)		
Opening balance	47,611	1,595,652	110,507	838,283	242,984	2,835,037
Additions during the year	1,104,866	1,631,281	629,439	1,478,901	648,330	5,492,817
Transferred to operating fixed	. ,	. ,	,		,	. ,
assets during the year	(774,855)	(1,409,725)	(128,516)	(317,370)	(210,992)	(2,841,458)
Closing balance	377,622	1,817,208	611,430	1,999,814	680,322	5,486,396

6.3.1 Majority of the closing balance of capital work-in-progress pertains to projects relating to Soda Ash business.

7.	INTANGIBLE ASSETS	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) 1 '000)
	Intangible assets - at net book value	7.1	2,979,001	1,682,954
7.1	Following are the details of intangible assets:			
	Brands Goodwill Others		2,726,726 206,374 45,901 2,979,001	1,437,679 206,374 <u>38,901</u> 1,682,954
7.2	Addition to intangible assets	7.3	1,306,429	31,066

7.3 This mainly includes additions as a result of business acquisition as disclosed in note 5.2 of these unconsolidated condensed interim financial statements.

8.	LONG-TERM INVESTMENTS	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) '000)
	Unquoted - at cost Subsidiaries - Lucky Core PowerGen Limited (wholly owned) 7,100,000 (June 30, 2024: 7,100,000) ordinary shares of PKR 100 each Provision for impairment		710,000 (209,524) 500,476	710,000 (209,524) 500,476
	 Lucky Core Ventures (Private) Limited (wholly owned) 10,000 (June 30, 2024: 10,000) ordinary shares of face value of PKR 10 each 		100	100
	 Lucky TG (Private) Limited [51% owned (June 30, 2024: 51% owned)] 510,000 (June 30, 2024: 510,000) ordinary shares of face value of PKR 10 each 		5,100	5,100
	Associate - NutriCo Morinaga (Private) Limited [22.2% holding (June 30, 2024: 24.5% holding)] 20,121,621 (June 30, 2024: 20,121,621) ordinary shares of face value of PKR 100 each	8.1	1,904,315	1,904,315
	Others Equity - Arabian Sea Country Club Limited 250,000 (June 30, 2024: 250,000) ordinary shares of PKR 10 each		<u> </u>	<u>2,500</u> 2,412,491

- **8.1** During the period, NutriCo Morinaga (Private) Limited (NutriCo) issued right shares which were not subscribed / declined by the Company which consequently reduced the shareholding percentage of the Company in NutriCo from 24.5% to 22.2%.
- 8.2 The principal place of business of all the investees is in Pakistan.

9.	STOCK-IN-TRADE	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) n '000)
	Raw and packing material includes goods-in-transit amounting to			
	PKR 1,959.793 million (June 30, 2024: PKR 1,917.291 million)		9,790,781	7,890,203
	Work-in-process		594,986	483,585
	Finished goods include goods-in-transit amounting to PKR 328.669 million			
	(June 30, 2024: PKR 485.710 million)	9.1	8,234,391	7,253,716
			18,620,158	15,627,504
	Provision for slow moving and obsolete stock-in-trade		(174,705)	(232,113)
			18,445,453	15,395,391

9.1 Stock at cost amounting to PKR 296.070 million (June 30, 2024: PKR 18.538 million) is measured at net realisable value. The related expense amounting to PKR 11.951 million (June 30, 2024: PKR 7.620 million) has been recognised in cost of sales.

10.	TRADE DEBTS	Note	March 31, 2025 (Unaudited) (PKR ir	June 30, 2024 (Audited) 1 '000)
	Considered good			
	- Secured - Unsecured		1,444,733	2,076,145
	Due from associated companies		46,236	38,551
	Others		5,233,665	4,459,102
			6,724,634	6,573,798
	Considered doubtful		249,406	170,820
			6,974,040	6,744,618
	- Allowance for expected credit losses (ECL)	10.1	(249,406)	(170,820)
	- Provision for price adjustments, discounts and sales returns		(1,033,425)	(998,493)
			(1,282,831)	(1,169,313)
			5,691,209	5,575,305

10.1 During the period, the Company has recognised allowance for ECL amounting to PKR 82.561 million (June 30, 2024: PKR 51.039 million).

11.	OTHER RECEIVABLES	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) n '000)
	Considered good		
	Sales tax	1,005,831	1,815,805
	Commission and discounts receivable	7,336	3,185
	Due from subsidiaries	1,224	680
	Due from associated companies	9,000	-
	Accrued interest income	2,818	6,814
	Receivable from principal	133,025	125,407
	Others	234,673	257,771
		1,393,907	2,209,662
	Considered doubtful	43,112	32,466
		1,437,019	2,242,128
	Allowance for ECL	(43,112)	(32,466)
		1,393,907	2,209,662

12.	SHORT TERM INVESTMENTS	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) '000)
	At fair value through profit or loss			
	Investment in mutual funds	12.1	18,348,717	15,561,484
	At amortised cost			
	Term deposits receipts		<u> </u>	127,000 15,688,484

12.1 This includes unrealised revaluation gain of PKR 1,548.512 million (June 30, 2024: Nil) arising on remeasurement of investment in mutual funds.

13.	LONG-TERM LOANS	March 31, 2025 (Unaudited) (PKR ir	June 30, 2024 (Audited) 1 '000)
	Long-term loans	11,369,567	4,895,794
	Current portion shown under current liabilities	(1,054,484)	(909,446)
		10,315,083	3,986,348

13.1 There is no material change in the terms and conditions of the long-term loans as disclosed in the Company's annual audited unconsolidated financial statements for the year ended June 30, 2024. During the period, the Company has obtained Diminishing Musharakah of PKR 6,867.400 million from various banks to finance acquisition of certain assets of Pfizer Pakistan Limited as explained in note 5 and to manage capital expenditure requirements of its Soda Ash business. Repayment of these loans is to be made in quarterly installments in 7 years including 1 to 2 years of grace period. The mark-up on these loans is charged at KIBOR plus 0.05% to KIBOR plus 0.2% per annum. The loans are secured against fixed assets of the Company.

14.	DEFERRED TAX LIABILITY - NET	March 31, 2025 (Unaudited) (PKR ir	June 30, 2024 (Audited) 1 '000)
	Deductible temporary differences Provisions for allowance for ECL and others Retirement benefit fund provisions	(638,176) (136,448)	(636,120) (140,301)
	Taxable temporary differences Property, plant and equipment and intangibles Investments in mutual funds	2,577,193 	2,894,352 - 2,117,931
15.	DEFERRED INCOME - GOVERNMENT GRANT		
	Government grant Current portion of government grant	709,010 (187,136) 521,874	863,428 (204,473) 658,955
16.	SHORT-TERM FINANCING		
	Export refinance facility (ERF) Short-term running finance - secured	2,400,000 11,304,364 13,704,364	2,517,578 9,216,926 11,734,504

16.1 There is no material change in the terms and conditions of short-term borrowings and running finances as disclosed in the Company's annual audited unconsolidated financial statements for the year ended June 30, 2024.

4-		March 31, 2025 (Unaudited)	June 30, 2024 (Audited)
17.	CONTINGENCIES AND COMMITMENTS	(PKR in	000)
17.1	Contingencies		
17.1.1	Claims against the Company not acknowledged as debt are as follows:		
	Local bodies	84,500	84,500

17.1.2 There are no material changes in the status of contingencies as reported in the annual audited unconsolidated financial statements for the year ended June 30, 2024, except for the following:

Others

- (a) The Federal Board of Revenue (FBR) finalised sales tax proceedings vide order dated July 29, 2024, whereby, input tax of PKR 90.86 million was disallowed. Being aggrieved by the order, the Company filed an appeal before the Tribunal which vide appellate order dated December 11, 2024 has remanded back the case to FBR.
- (b) Sales tax audit for July 2018 to June 2019 has been finalised by the FBR vide order dated October 22, 2024 raising sales tax demand of PKR 23.295 million on various issues including adjustment of inadmissible input tax and non-payment of sales tax on sale of fixed assets. The Company has filed an appeal before the Tribunal which is pending adjudication, however, the sales tax demand has been paid under protest.
- (c) There has been a dispute between the Company and the Collectorate of Customs regarding HS code classification of various consignments relating to Power Generation Projects. A petition was filed by the Company before the Sindh High Court against the wrong assessment of the consignment along with the submission of bank guarantees for the differential amount of PKR 1,095.290 million with the Nazir of the Sindh High Court in order to release import shipments. Subsequently, the Sindh High Court has disposed off the petition vide order dated January 13, 2025 whereby the case has been remanded back to the Classification Centre for deciding the correct classification of consignment relating to Power Generation Projects. Being aggrieved, the Company has filed a petition before the Supreme Court of Pakistan which is yet to be fixed for hearing.

The Company based on the opinion of advisors is confident that the above cases would be decided in Company's favor. Accordingly, no provision in respect of these matters has been made in these unconsolidated condensed interim financial statements.

17.2	Commitments	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) n '000)
17.2.1	Commitments in respect of capital expenditure	1,497,018	4,928,711
17.2.2	Commitments for rentals under ljarah contracts in respect of vehicles are as follows:		
	Year 2023-24 2024-25 2025-26 2026-27 2027-28 2028-29 Payable not later than one year Payable later than one year but not later than five years	5,067 7,195 7,663 8,161 8,691 36,777 5,067 31,710 36,777	6,756 7,195 7,663 8,161 8,691 - - 38,466 6,756 31,710 38,466
17.3	Other commitments		
17.3.1	Outstanding letter of credit - unutilised PKR 17,295.781 million (June 30, 2024: PKR 17,287.663 million)	10,311,233	11,662,337
17.3.2	Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.020 million)	5,188,925	4,357,696
17.3.3	Commitments in respect of post dated cheques	1,072,955	1,081,752

2,095,740

2.180.240

1.512.755

1.597.255

15 Lucky Core Industries Limited

TS
Ч
ົ
Ш
2
Ę
ż
ш
Σ
σ
ш
ົ
(ľ)
ž
Ē
2
2
Ш
•
ö
-
ω
~

Operating segments as disclosed below do not incorporate the results of subsidiaries as these are unconsolidated condensed interim financial statements of the Company:

								ſ				
		Poly	Polyester			Soda	Soda Ash			Pha	Pharma	
	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
Turnover - note 18.1, 18.2 & 18.3 11,453,025	11,453,025	37,969,208	12,597,497	35,817,396	12,006,126	36,091,923	13,929,246	42,999,653	6,302,338	19,242,452	4,270,169	12,082,391
Sales tax	(1,721,534)	(5,714,709)	(1,779,693)	(5,065,972)	(1,619,005)	(4,643,891)	(1,689,509)	(5,071,363)	(44,564)	(137,678)	(41,347)	(119,600)
Commission and discounts / price adjustment	(91,755)	(446,020)	(157,778)	(399,813)	(544,941)	(1,385,140)	(517,387)	(1,701,405)	(1,151,290)	(3,568,912)	(1,074,717)	(3,026,986)
	(1,813,289)	(6,160,729)	(1,937,471)	(5,465,785)	(2,163,946)	(6,029,031)	(2,206,896)	(6,772,768)	(1,195,854)	(3,706,590)	(1,116,064)	(3,146,586)
Net turnover	9,639,736	31,808,479	10,660,026	30,351,611	9,842,180	30,062,892	11,722,350	36,226,885	5,106,484	15,535,862	3,154,105	8,935,805
Cost of sales - note 18.1 & 19	(9,035,280)	(29,718,842)	(9,902,090)	(28,750,843)	(7,343,708)	(21,656,868)	(8,338,322)	(26,082,375)	(3,106,664)	(9,524,829)	(1,862,205)	(5,548,378)
Gross profit	604,456	2,089,637	757,936	1,600,768	2,498,472	8,406,024	3,384,028	10,144,510	1,999,820	6,011,033	1,291,900	3,387,427
Selling and distribution expenses	(85,087)	(239,276)	(56,051)	(172,552)	(334,058)	(1,430,673)	(646,672)	(1,946,867)	(782,456)	(2,099,292)	(519,165)	(1,435,859)
Administration and general expenses	(37,389)	(131,018)	(40,162)	(112,826)	(253,619)	(795,516)	(277,142)	(916,207)	(182,307)	(484,298)	(198,266)	(410,052)
Operating results	481,980	1,719,343	661,723	1,315,390	1,910,795	6,179,835	2,460,214	7,281,436	1,035,057	3,427,443	574,469	1,541,516
							Polyester	ster	Soda Ash	Ash	Pharma	ma
							March 31, 2025 (Unaudited)	June 30, 2024 (Audited)	March 31, 2025 (Unaudited)	June 30, 2024 (Audited)	March 31, 2025 (Unaudited)	June 30, 2024 (Audited)
									(PKR i	(PKR in '000)		
Segment assets							17,476,112	16,212,254	57,295,966	51,179,871	19,059,991	10,285,830

Segment liabilities

5,558,027

12,578,986

14,036,604 14,717,302 **11,105,274** 10,409,001

_						Unai	Unaudited					
		Anima	Animal Health			Chemicals and Agri Sciences	Agri Sciences			Com	Company	
	For the three months period ended March	For the nine months period ended March	For the three months period ended March	For the nine months period ended March	For the three months period ended March	For the nine months period ended March	For the three months period ended March	For the nine months period ended March	For the three months period ended March	For the nine months period ended March	For the three months period ended March	For the nine months period ended March
	31, 2025	31, 2025	31, 2024	31, 2024	31, 2025	31, 2025	31, 2024	31, 2024	31, 2025	31, 2025	31, 2024	31, 2024
						(PKR	- (PKR in '000)					
Turnover - note 18.1, 18.2 & 18.3	2,559,622	7,100,423	2,557,831	7,119,901	4,337,644	12,303,186	4,689,498	13,422,409	36,658,755	112,665,289	38,039,960	111,345,731
Sales tax	(56,566)	(173,295)	(46,222)	(134,655)	(449,694)	(1,274,034)	(421,058)	(1,231,910)	(3,891,363)	(11,943,607)	(3,977,829)	(11,623,500)
commission and discounts / price adjustment	(883,525)	(2,428,658)	(700,112)	(1,844,722)	(275,072)	(799,864)	(553,295)	(1,468,481)	(2,946,583)	(8,628,594)	(3,003,289)	(8,441,407)
	(940,091)	(2,601,953)	(746,334)	(1,979,377)	(724,766)	(2,073,898)	(974,353)	(2,700,391)	(6,837,946)	(20,572,201)	(6,981,118)	(20,064,907)
Net turnover Cost of sales - note 18.1 & 19	1,619,531 (1,050,974)	4,498,470 (2,934,600)	1,811,497 (1,289,867)	5,140,524 (3,631,049)	3,612,878 (2,593,686)	10,229,288 (7,411,052)	3,715,145 (2,655,901)	10,722,018 (7,542,895)	29,820,809 (23,130,312)	92,093,088 (71,204,288)	31,058,842 (24,044,104)	91,280,824 (71,459,521)
Gross profit	568,557	1,563,870	521,630	1,509,475	1,019,192	2.818,236	1,059,244	3,179,123	6,690,497	20,888,800	7,014,738	19,821,303
Selling and distribution expenses	(227,425)	(678,322)	(205,044)	(629,430)	(385,680)	(1,068,421)	(427,853)	(1,176,578)	(1,814,706)	(5,515,984)	(1,854,785)	(5,361,286)
Administration and general expenses	(36,307)	(103,042)	(34,008)	(96,710)	(96,986)	(249,697)	(90,583)	(325,876)	(606,608)	(1,763,571)	(640,161)	(1,861,671)
Operating results	304,825	782,506	282,578	783,335	536,526	1,500,118	540,808	1,676,669	4,269,183	13,609,245	4,519,792	12,598,346
							Animal Health	Health	Chemicals and Agri Sciences	Aari Sciences	Company	
							March 31, 2025 // Incordified/	June 30, 2024 (A.:ditod)	March 31, 2025 // Incondited/	June 30, 2024 / A.:ditod)	March 31, 2025 // Incordified/	June 30, 2024 / A.:ditecd)
							(oliauulicu)	(noinnu)		(המווחהר)	(oliauuleu)	(manimu)
Segment assets							7,125,809	6,182,262	16,364,579	14,580,685	117,322,457 1 012 015	98,440,902 1 012 015
Intersegment eliminations											(21,727,741)	(16,787,183)
											97,506,731	83,565,734
Segment liabilities							1,083,229	784,290	2,799,396	2,624,643	41,603,489	34,093,263
Unallocated liabilities Intersegment eliminations											31,43/,6/3 (21,727,741)	22,683,648 (16,787,183)
											51,313,421	39,989,728

		For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
18.1	Turnover and cost of sales		(Unau		
10.1			(PKK II	1 000)	
	Inter-segment sales and purchases have been eliminated from the total		41,903	4,281	96,019
18.2	Turnover includes export sales made to various countries amounting to:	1,371,494	5,782,067	2,463,712	8,701,673
18.3	Turnover includes commission / toll income amounting to:	22,566	66,047	15,064	20,420
19.	COST OF SALES				
	Opening stock of raw and packing materials - note 9	8,663,834	7,890,203	9,189,286	9,873,842
	Purchases	15,342,700	45,773,820	15,802,584	42,759,950
		24,006,534	53,664,023	24,991,870	52,633,792
	Closing stock of raw and packing materials - note 9	(9,790,781)	(9,790,781)	(10,090,151)	(10,090,151)
	Raw and packing materials consumed	14,215,753	43,873,242	14,901,719	42,543,641
	Manufacturing costs	6,569,211	21,827,497	7,420,601	22,159,760
		20,784,964	65,700,739	22,322,320	64,703,401
	Opening stock of work-in-process - note 9	716,197	483,584	646,812	450,271
		21,501,161	66,184,323	22,969,132	65,153,672
	Closing stock of work-in-process - note 9	(594,986)	(594,986)	(515,714)	(515,714)
	Cost of goods manufactured	20,906,175	65,589,337	22,453,418	64,637,958
	Opening stock of finished goods - note 9	9,957,370	7,253,716	6,993,917	8,407,429
	Finished goods purchased	501,158	6,595,626	793,051	4,610,416
		31,364,703	79,438,679	30,240,386	77,655,803
	Closing stock of finished goods - note 9	(8,234,391)	(8,234,391)	(6,196,282)	(6,196,282)
		23,130,312	71,204,288	24,044,104	71,459,521

20. OTHER INCOME

This includes PKR 1,840.128 million (March 31, 2024: 2,012.976 million) on account of income from investment in mutual funds.

		For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			(Unau	,	
21.	BASIC AND DILUTED EARNINGS PER SHARE		(PKR II	n '000)	
	Profit for the period	2,587,028	8,805,361	2,893,327	7,933,157
			(Number o	of shares)	
	Weighted average number of ordinary shares outstanding during the period	92,359,050	92,359,050	92,359,050	92,359,050
			(PK	(R)	
	Basic and diluted earnings per share	28.01	95.34	31.33	85.89

		Note	For the nine months period ended March 31, 2025	For the nine months period ended March 31, 2024
			(Unau	dited)
22.	CASH GENERATED FROM OPERATIONS		(PKR i	n '000)
	Profit before final taxes and income tax		14,068,901	12,080,268
	Adjustments for: Depreciation and amortisation Gain on disposal of operating fixed assets Gain on bargain purchase Provision for non-management staff gratuity and eligible retired employees' medical scheme Provision for staff retirement benefit plan Interest income Interest expense Income from mutual funds Provision no longer required written-back Provision for slow moving and obsolete stock-in-trade Allowance for expected credit losses Unwinding of staff loans Deferred income		2,774,565 (91,472) (172,183) 32,418 40,393 (175,733) 1,754,955 (291,616) - - 5,368 83,253 (663,729)	2,556,930 (14,472) - 34,476 33,412 (309,828) 2,732,755 (2,012,976) (58) 101,400 30,011 - (139,573)
	Deferred income - Government grant Provision for slow moving and obsolete stores, spares and consumables		(154,418) <u>9,056</u> 17,219,758	4,719
	Movement in:		17,219,750	15,097,004
	Working capital Long-term loans Long-term deposits and other assets Cash generated from operations	22.1	2,289,893 (43,244) (17,682) 19,448,725	6,552,930 (115,459) (1,771) 21,532,764
22.1	Movement in working capital			
	(Increase) / Decrease in current assets Stores, spares and consumables Stock-in-trade Trade debts Loans and advances Trade deposits and short-term prepayments Other receivables		1,173,978 (1,761,301) (198,465) (368,649) 319,770 <u>811,759</u> (22,908)	2,388,391 1,827,995 57,117 (400,321) 1,792,490 1,551,872 7,217,544
	Increase in current liabilities Trade and other payables		<u>2,312,801</u> 2,289,893	(664,614)
23.	TRANSACTIONS WITH RELATED PARTIES			,,,

23. TRANSACTIONS WITH RELATED PARTIES

The related parties comprise the Holding company and related group companies, associated companies, subsidiary companies, directors of the Company, companies where directors also hold directorship, key employees and staff retirement funds. All the transactions with related parties are entered into at agreed terms duly approved by the Board of Directors of the Company. Details of transactions with related parties, other than those which have been specifically disclosed elsewhere in these unconsolidated condensed interim financial statements are as follows:

Relationship with the Company	Nature of transaction	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			•	,	
Holding Company	Dividend paid Sale of goods and materials Purchase of goods, materials	1,727,132 6,908	3,403,466 23,330	1,371,546 11,159	3,047,880 31,526
	and services Reimbursement of expenses	51,441 565	156,590 565	17,998 -	38,058 -

Report for the Nine Months Ended March 31, 2025

Relationship with the Company	Nature of transaction	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			(Unaud (PKR ir		
Subsidiary Companies	Purchase of goods, materials and services Sale of goods, materials and assets Reimbursement of expenses	353,343 45,250 -	1,219,933 119,105 543	341,714 495 -	1,285,968 91,097 680
Associated Companies	Purchase of goods, materials and services Sale of goods and materials Reimbursement of expenses Dividend paid Donations paid	392,347 1,030,251 9,013 835,356 5,158	626,636 3,752,007 34,777 1,644,261 10,503	73,351 1,005,863 13,063 661,832 945	250,873 5,081,422 29,567 1,470,737 16,191
Others	Staff retirement benefits - contribution	138,338	390,647	114,386	336,394
Key management personnel	Remuneration paid Post employment benefits Director's meeting fee Dividend paid	82,478 12,730 959 25,136	502,771 38,391 4,258 49,379	126,454 13,353 1,922 19,835	535,256 38,958 3,816 44,078

24. FINANCIAL RISK MANAGEMENT

The Company's financial risk management objective and policies are consistent with that disclosed in the annual audited unconsolidated financial statements for the year ended June 30, 2024.

25. FAIR VALUE OF FINANCIAL INSTRUMENTS

25.1 Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Consequently, differences can arise between carrying values and the fair value estimates.

Underlying the definition of fair value is the presumption that the Company is a going concern without any intention or requirement to curtail materially the scale of its operations or to undertake a transaction on adverse terms.

The fair value of investments in units of open-end collective investment schemes (mutual funds) are based on the net assets value quoted by the respective funds and the Mutual Funds Association of Pakistan at each reporting date. The estimated fair value of all other financial assets and liabilities are considered not to be significantly different from carrying values as the items are either short-term in nature or are periodically repriced except for lease liabilities.

25.2 The Company classifies financial assets using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

(i) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;

(ii) Level 2: inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

(iii) Level 3: inputs for the asset or liability that are not based on observable market data (i.e. unobservable inputs).

As of the reporting date, except for the Company's investment in mutual funds (which is valued under level 2), none of the financial instruments are carried at fair value in these unconsolidated condensed interim financial statements. There were no transfers between level 1, 2 or 3 of the fair value hierarchy during the year.

		As a March 31, 2	2025 (Unaudited	d)
Assets	Level 1	Level 2	Level 3	Total
		(PKR i	n '000)	
Financial assets - fair value through profit or loss: - Short-term investments (units of mutual fund)		18,348,717		18,348,717

36

	As at June 30, 2024 (Audited)			
Assets	Level 1 Level 2 Level 3 Total	1		
	(PKR in '000)			
Financial assets - fair value through profit or loss: - Short-term investments (units of mutual fund)	- 15,561,484 - 15,561,4	484		

26. DATE OF AUTHORISATION

These unconsolidated condensed interim financial statements were authorised for issue in the Board of Directors meeting held on April 22, 2025.

27. GENERAL

- 27.1 Figures have been rounded off to the nearest thousand PKR except as stated otherwise.
- 27.2 Wherever considered necessary, corresponding figures have been reclassified for the purpose of comparison and improved presentation. However, the impacts are not material.
- 27.3 Non-cash investing and financing activities include additions of right-of-use assets.

Muhammad Sohail Tabba Chairman / Director

Ach Jon

Asif Jooma Chief Executive



Atif Aboobukar Chief Financial Officer



Lucky Core Industries Limited and its Subsidiary Companies Consolidated Financial Statements

38

Review of the Directors (Consolidated)

for the Nine Months ended March 31, 2025

The Directors are pleased to present their review together with the unaudited Group results of Lucky Core Industries Limited for the nine-months ended March 31, 2025. The Lucky Core Industries group comprises Lucky Core Industries Limited, its subsidiaries: Lucky Core PowerGen Limited (PowerGen), Lucky TG (Private) Limited (Lucky TG), Lucky Core Ventures (Private) Limited (LCV) and its associated concern; NutriCo Morinaga (Private) Limited (NMPL).

The Director's report, which provides a commentary on the performance of Lucky Core Industries Limited for the nine-months ended March 31, 2025, has been presented separately.

The Net Turnover of PowerGen for the nine months at PKR 1,118 million is 5% lower as compared to the SPLY. Decrease in net

revenue was primarily attributed to supressed HFO price by 14% on the back of decrease in crude oil prices as compared to the SPLY. The Operating Result at PKR 85 million was higher by 5% compared to the SPLY due to better cost management.

On a consolidated basis, Net Turnover for the nine months at PKR 92,049 million is higher by 1% compared to the SPLY. Whereas the Operating Result at PKR 13,695 million is higher by 8% compared to the SPLY. PAT for the nine months at PKR 8,910 million is 12% higher than the SPLY, whereas EPS attributed to the owners of the holding company at PKR 96.47 is 12% higher than the SPLY owing to improved operating performance.

Arr Jon

Asif Jooma Chief Executive

Muhammad Sohail Tabba Chairman

Date: April 22, 2025 Karachi

ڈائر بیطر زکاجائزہ 31 مارچ 2025 کو ختم ہونے والی 9 ماہ کی مدت کے لیے۔ کنسولیڈیٹڈ

HFO کی قیمت میں %14 کی کمی کی وجہ ہے ہوئی جو گزشتہ سال کے اسی عرصے کے مقابلے میں خام تیل کی قیمتوں میں کمی کے لیں منظر میں ہوئی ہے۔ آپر ٹینگ منافع 85 ملین روپے ہے جو بہتر کاسٹ مینجمنٹ کے سبب گزشتہ سال کے اسی عرصے کے مقابلے میں %5 زیادہ ہے۔

مجموعی بنیادوں پر 9ہاہ کے لیے خالص مجموعی فروخت 92,049 ملین روپے رہی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں 10% زیادہ ہے، جبکہ آپر ٹینگ منافع 13,695 ملین روپے ہے جو گزشتہ سال کے اسی عرصے کے مقابلے میں 18% زیادہ ہے۔ نوماہ کی مدت کے لیے منافع بعد از شیکس (PAT)900,8 ملین روپ ہے جو گزشتہ سال کے اسی عرصے کے مقابلے میں 12% دیادہ ہے، جبکہ ہولڈ نگ کمپنی کے مالکان سے منسوب آمدنی فی حصص (EPS)96.47 دوپے ہے جو بہتر آپر ٹینگ کار کر دگی کی بدولت گزشتہ سال کے اسی عرصے کے مقابلے میں 12% زیادہ ہے۔ ڈائر بکٹر ز 1 3مار چ 2025 کو ختم ہونے والی 9ماہ کی مدت کے لئے لگی کور انڈسٹر یز کمیٹڈ کے غیر آڈٹ شدہ گروپ نتائج کے ساتھ اپنا جائزہ بمسرت پیش کرتے ہیں۔ لگی کور انڈسٹر یز گروپ میں لگی کور انڈسٹر یز لمیٹڈ ،اس کے ذیلی ادارے: لگی کور پاور جن لمیٹڈ (پاور جن)، لگی ٹی جی (پرائیویٹ) کمیٹڈ (لگی ٹی جی)، لگی کور وینچر ز (پرائیویٹ) کمیٹڈ (این ایم پی (ایل سی وی) اور اس سے وابستہ ادارہ: نیوٹری کو مورینا گا (پرائیویٹ) کمیٹڈ (این ایم پی ایل) شامل ہیں۔

ڈائر کیٹر ز کی رپورٹ کو، جس میں 1 3مارچ 2025 کو ختم ہونے والی 9ماہ کی مدت کے لئے لکی کورانڈسٹریز کمیٹڈ کی کار کردگی پر تیصر ہ موجود ہے، علیحدہ پیش کیا گیا ہے۔

9ماہ کی مدت کے لیے پاور جن کی خالص مجموعی فروخت 1,118 ملین روپے رہی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں %55 کم ہے۔ نیٹ ریونیو میں کمی بنیاد ی طور پر

Ard som

آصف جمعہ چیف ایگزیکٹو

م محمد سهمیل شاب چیئر مین

تاريخ:22 اپريل 2025 كراچي

Consolidated Condensed Interim Statement of Financial Position

As at March 31, 2025

	Note	March 31, 2025	June 30, 2024
		(Unaudited)	(Audited)
		(PKR in	'000)
ASSETS			
Non-current assets	0	00.047.070	00 000 700
Property, plant and equipment	6	38,247,972	29,929,796
Intangible assets	7	2,979,001	1,682,954
Right-of-use assets		268,042	182,457
	0	41,495,015	31,795,207
Long-term investments	8	10,856,138 850,412	10,827,265
Long-term loans Long-term deposits and other assets		990,043	807,512 287,883
Long-term deposits and other assets	I	12,696,593	11,922,660
		54,191,608	43,717,867
Current assets		54,191,000	43,717,007
Stores, spares and consumables		5,005,692	5,994,851
Stock-in-trade	9	18,517,088	15,466,376
Trade debts	10	5,710,336	5,593,143
Loans and advances	10	1,418,385	1,043,727
Short-term deposits and prepayments		755,789	1,051,893
Other receivables	11	1,424,416	2,220,907
Short-term investments	12	18,762,535	15,709,822
Cash and bank balances	12	735,517	1,576,667
		52,329,758	48,657,386
Total assets		106,521,366	92,375,253
EQUITY AND LIABILITIES Share capital and reserves			
Authorised capital 1,500,000,000 (June 30, 2024: 1,500,000,000) ordinary shares of PKR 10 each		15,000,000	15,000,000
lssued, subscribed and paid-up capital 92,359,050 (June 30, 2024: 92,359,050) ordinary shares of PKR 10 each		923,591	923,591
Capital reserves		18,309,643	18,309,643
Revenue reserve - unappropriated profit		32,935,488	30,213,786
Attributable to the equity holders of the holding company		52,168,722	49,447,020
Non-controlling interests		11,057	10,725
Total equity		52,179,779	49,457,745
Non-current liabilities Staff retirement benefits		116,222	115,549
Long-term loans	13	10,315,083	3,986,348
_ease liabilities	-	181,325	157,478
Deferred tax liability - net	14	5,677,391	5,596,926
Deferred income - government grant	15	521,874	658,955
Current liabilities		16,811,895	10,515,256
Frade and other payables		16,715,389	14,311,951
Accrued mark-up		775,713	576,227
Short-term financing	16	13,704,364	11,734,504
Current portion of long-term loans	10	1,054,484	909,446
			38,547
Jurrent portion of lease liabilities		74.058	30.347
•		74,058 187,136	· · ·
Current portion of deferred income - government grant		187,136	204,473
Current portion of deferred income - government grant Faxation - net		187,136 4,860,666	204,473 4,490,277
Current portion of deferred income - government grant Taxation - net		187,136 4,860,666 157,882	204,473 4,490,277 136,827
Current portion of lease liabilities Current portion of deferred income - government grant Taxation - net Unclaimed dividend Total equity and liabilities		187,136 4,860,666	204,473 4,490,277

Contingencies and commitments

The annexed notes from 1 to 27 form an integral part of these consolidated condensed interim financial statements.

Muhammad Sohail Tabba Chairman / Director

Asy som

Chief Executive

Asif Jooma

Report for the Nine Months Ended March 31, 2025

Atif Aboobukar Chief Financial Officer

Consolidated Condensed Interim Statement of Profit or Loss (Unaudited) For the Three Months and Nine Months Period Ended March 31, 2025

Gross profit Selling and distribution expenses 18 6,716,721 20,976,506 7,037,362 19,902,591 Administration and general expenses 18 (607,303) (1,766,000) (640,190) (1,863,765) Operating result 18 4,294,712 13,694,523 4,542,387 12,677,740 Finance costs (454,477) (2,0301) (28,468) 9,146 (30,849) Workers' profit participation fund Workers' effare fund (113,774) (27,33,206 (12,1149) (32,92,66 Workers' effare fund (113,774) (26,7695) (70,173) (14,908) (329,266 Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,629 881,553 2,692,612 Share of (loss) / profit from associate 11,51694 14,183,063 4,425,764 12,056,926 Profit before final taxes (121) (12,457) (20,692,624 (624,311) Profit before final taxes (121) (12,657) (208,642) (624,311) Profit before final taxes (121) (1,540,874) (5,179,849) <th></th> <th>Note</th> <th>For the three months period ended March 31, 2025</th> <th>For the nine months period ended March 31, 2025</th> <th>For the three months period ended March 31, 2024</th> <th>For the nine months period ended March 31, 2024</th>		Note	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
Cost of sales 18 & 19 (23,087,054) (71,072,963) (24,002,637) (71,190,951) Gross profit 6,716,721 20,976,506 7,037,362 19,902,593 Selling and distribution expenses 18 (1,814,706) (5,515,983) (1,854,785) (1,854,785) Administration and general expenses 18 (4294,712) 13,694,523 4,542,387 12,677,740 Finance costs (454,477) (1,754,955) (74,475) (2,733,205) Exchange (loss) / gain (454,477) (1,3774) (329,263) (186,444) Workers' profit participation fund (113,174) (329,265) (744,475) (12,733,205) Workers' welfare fund (113,774) (13,774) (12,3149) (329,262) (3,207,122) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate 20 536,551 2,816,829 881,553 2,692,812 Taxation - Income tax 4,151,694 14,163,063 4,425,764 12,056,927				(PKR i	n '000)	
Cost of sales 18 & 19 (23,087,054) (71,072,963) (24,002,637) (71,190,951) Gross profit 6,716,721 20,976,506 7,037,362 19,902,593 Selling and distribution expenses 18 (1,814,706) (5,515,983) (1,854,785) (1,854,785) Administration and general expenses 18 (4294,712) 13,694,523 4,542,387 12,677,740 Finance costs (454,477) (1,754,955) (74,475) (2,733,205) Exchange (loss) / gain (454,477) (1,3774) (329,263) (186,444) Workers' profit participation fund (113,174) (329,265) (744,475) (12,733,205) Workers' welfare fund (113,774) (13,774) (12,3149) (329,262) (3,207,122) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate 20 536,551 2,816,829 881,553 2,692,812 Taxation - Income tax 4,151,694 14,163,063 4,425,764 12,056,927	Notturnovor	10	20 902 775	02 040 460	21 020 000	01 002 542
Selling and distribution expenses 18 (1,814,706) (5,515,983) (1,854,785) (5,361,286) Administration and general expenses 18 (607,303) (1,766,000) (640,190) (1,863,565) Operating result 18 4,294,712 13,694,523 4,542,387 12,677,740 Finance costs (23,301) (1,754,955) (744,475) (2,733,200) Workers' profit participation fund (113,774) (1378,906) (12,3149) (329,265) Workers' welfare fund (113,774) (13,774) (14,908) (186,447) Other charges (676,200) (257,695) (3,207,123) (320,126) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (121) (12,657) (208,642) (624,311) Profit before final taxes and income tax 4,151,573 14,151,573 14,170,406 4,227,712 11,432,617 Taxation - Income tax (1,540,874) (5,260,315) (1,318,922) (3,765,977) (3,66						(71,190,951)
Selling and distribution expenses 18 (1,814,706) (5,515,983) (1,854,785) (5,361,286 Administration and general expenses 18 (607,303) (1,766,000) (640,190) (1,863,565 Operating result 18 4,294,712 13,694,523 4,542,387 12,677,740 Finance costs (1,754,955) (744,475) (2,733,200) (2,733,200) (1,863,468) 9,146 130,897 Workers' profit participation fund (113,774) (13,774) (17,54,955) (744,475) (2,733,200) Workers' welfare fund (113,774) (13,774) (17,54,955) (70,173) (14,908) (186,447) Other charges (667,200) (2,573,345) (97,0559) (3,207,128) (3,207,128) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (12,11) (12,657) (208,642) (624,311) Profit before final taxes (11,51,573) 14,151,573 14,170,406 4,217,122 11,432,617						40.000.504
Administration and general expenses 18 (607,303) (1,766,000) (640,190) (1,863,565 Operating result 18 4,294,712 13,694,523 4,542,387 12,677,740 Finance costs (1,754,955) (744,475) (2,733,206) (329,326) (123,149) (329,266) (130,897) Workers' profit participation fund (113,774) (13,774) (17,54,955) (70,173) (166,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (199,321) (186,447) (186,447) (186,447) (186,447) (186,447) (199,321) (186,447) (186,447) (186,447) (186,447) (186,447) (199,321) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (186,447) (199,321) (3,207,122) (3,207,122) (1,21,12) (11,31,73) (116,552) (2,61,73) (116,552) (2,61,73) (116,552) (2,61,73) (106,552) (2,76,17) (106,552) (12,11) (12,557) <td< td=""><td>-</td><td>19</td><td></td><td></td><td></td><td></td></td<>	-	19				
Finance costs (454,477) (1,754,955) (744,475) (2,733,205 Exchange (loss) / gain Workers' profit participation fund (20,301) (20,301) (28,468) 9,146 130,897 Workers' welfare fund Other charges (80,348) (267,695) (70,173) (146,447) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (1,1540,874) (1,2657) (208,642) (624,311 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - lincome tax (1,540,874) (5,179,849) (1,392,423) (3,765,971 Deferred (1,540,874) (5,179,849) (1,318,922) (3,493,914 Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0 2,608,624 8,910,091 2,898,200 7,938,703 Owners of the Holding Company 2,608,624 8,910,091 2,898,200 7,938,703	-					(3,361,286) (1,863,565)
Exchange (loss) / gain (20,301) (28,468) 9,146 130,897 Workers' profit participation fund (113,774) (378,906) (123,149) (329,266) Workers' welfare fund (80,348) (267,695) (70,173) (186,447) Other charges (676,200) (2,529,445) (970,559) (3,207,122) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311) Profit before income tax 4,151,694 14,183,0663 4,425,764 12,056,926 Current (1,540,874) (5,179,849) (1,392,423) (3,765,971) Deferred 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 2,608,624 8,910,091 2,898,200 7,938,703 <td>Operating result</td> <td>18</td> <td>4,294,712</td> <td>13,694,523</td> <td>4,542,387</td> <td>12,677,740</td>	Operating result	18	4,294,712	13,694,523	4,542,387	12,677,740
Exchange (loss) / gain (20,301) (28,468) 9,146 130,897 Workers' profit participation fund (113,774) (378,906) (123,149) (329,266) Workers' welfare fund (80,348) (267,695) (70,173) (186,447) Other charges (676,200) (2,529,445) (970,559) (3,207,122) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311) Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971) Deferred 2,608,624 8,910,091 2,898,200 7,938,703 Murchash 2,608,624 8,910,091 2,898,200 7,938,703	Finance costs		(454.477)	(1.754.955)	(744,475)	(2.733.209)
Workers' profit participation fund (113,774) (378,906) (123,149) (329,266) Workers' welfare fund (13,774) (80,348) (267,695) (70,173) (186,447) Other charges (676,200) (2,529,345) (970,559) (3,207,122) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502) Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Income tax (11,540,874) (12,657) (208,642) (624,311) Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,97) Deferred 2,608,624 8,910,091 2,898,200 7,938,703 Matributable to: 2,608,624 8,910,091 2,898,200 7,938,703 Owners of the Holding Company 2,608,624 8,910,091			1			130,897
Workers' welfare fund (80,348) (267,695) (70,173) (186,447) Other charges (7,300) (99,321) (41,908) (89,982) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502) Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,922 Taxation - Final taxes (121) (12,657) (208,642) (624,311) Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,974) Deferred (2,075) (6,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: Owners of the Holding Company 2,608,405 8,909,759 2,898,200 7,938,703 Non-controlling interests 219 332 1,941 </td <td></td> <td></td> <td></td> <td> ,</td> <td></td> <td>(329,265)</td>				,		(329,265)
Other charges (7,300) (99,321) (41,908) (89,096) Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311 Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,974) Deferred 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0 2,608,624 8,910,091 2,898,200 7,938,703 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 Mon-controlling interests 2,980,629 7,938,703 Owners of the Holding Company 2,608,624	Workers' welfare fund				(70,173)	(186,447)
Gain on bargain purchase 5 - 172,183 - - Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311) Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971) Deferred (2,075) (80,466) 73,501 272,057 (1,542,949) (5,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,898,200 7,938,703 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 0.00	Other charges		(7,300)	(99,321)	(41,908)	(89,098)
Other income 20 536,551 2,816,829 881,553 2,692,812 Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502 Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311 Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971 Deferred (1,542,949) (5,260,315) (1,318,922) (3,493,914 Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,624 8,910,091 2,898,200 7,938,703 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 Owners of the Holding Company 2,608,624 8,910,091 2,898,200 7,938,703 Non-controlling interests 2,608,624 8,910,091 2,898,200			(676,200)	(2,529,345)	(970,559)	(3,207,122)
Share of (loss) / profit from associate (3,369) 28,873 (27,617) (106,502) Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311) Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971) Current (1,540,874) (5,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 (PKR)	Gain on bargain purchase	5	-	172,183	-	-
Profit before final taxes and income tax 4,151,694 14,183,063 4,425,764 12,056,926 Taxation - Final taxes (121) (12,657) (208,642) (624,311 Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971 Deferred (1,542,949) (5,260,315) (1,318,922) (3,493,914 Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 (PKR)	Other income	20	536,551	2,816,829	881,553	2,692,812
Taxation - Final taxes (121) (12,657) (208,642) (624,311 Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971 Deferred (1,542,949) (5,260,315) (1,318,922) (3,493,914 Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700	Share of (loss) / profit from associate		(3,369)	28,873	(27,617)	(106,502)
Taxation - Final taxes (121) (12,657) (208,642) (624,311 Profit before income tax 4,151,573 14,170,406 4,217,122 11,432,617 Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971 Deferred (1,542,949) (5,260,315) (1,318,922) (3,493,914 Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700	Profit before final taxes and income tax		4,151,694	14,183,063	4,425,764	12,056,928
Taxation - Income tax (1,540,874) (5,179,849) (1,392,423) (3,765,971) Deferred (1,542,949) (5,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703	Taxation - Final taxes		(121)	(12,657)	(208,642)	(624,311)
Current (1,540,874) (5,179,849) (1,392,423) (3,765,971) Deferred (2,075) (80,466) 73,501 272,057 (1,542,949) (5,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703			4,151,573	14,170,406	4,217,122	11,432,617
Deferred (2,075) (80,466) 73,501 272,057 (1,542,949) (5,260,315) (1,318,922) (3,493,914) Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: 0wners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 Owners of the Holding Company 2,608,624 8,910,091 2,898,200 7,938,703 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 0			(1.540.874)	(5.179.849)	(1.392.423)	(3.765.971)
Profit for the period 2,608,624 8,910,091 2,898,200 7,938,703 Attributable to: Owners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703						272,057
Attributable to: Owners of the Holding Company Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703			(1,542,949)	(5,260,315)	(1,318,922)	(3,493,914)
Owners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703	Profit for the period		2,608,624	8,910,091	2,898,200	7,938,703
Owners of the Holding Company 2,608,405 8,909,759 2,896,259 7,937,003 Non-controlling interests 219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703 (PKR)	Attributable to:					
219 332 1,941 1,700 2,608,624 8,910,091 2,898,200 7,938,703			2,608,405	8,909,759	2,896,259	7,937,003
	Non-controlling interests		219	332	1,941	1,700
			2,608,624	8,910,091	2,898,200	7,938,703
Basic and diluted earnings per share 21 28.24 96.47 31.36 85.94				(Pł	(R)	
	Basic and diluted earnings per share	21	28.24	96.47	31.36	85.94

The annexed notes from 1 to 27 form an integral part of these consolidated condensed interim financial statements.

Muhammad Sohail Tabba

Acr Jon

Atif Aboobukar Chief Financial Officer

Asif Jooma Chief Executive

Consolidated Condensed Interim Statement of Comprehensive Income (Unaudited) For the Three Months and Nine Months Period Ended March 31, 2025

	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024 in '000)	For the nine months period ended March 31, 2024
Profit for the period	2,608,624	8,910,091	2,898,200	7,938,703
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	2,608,624	8,910,091	2,898,200	7,938,703
Attributable to:				
Owners of the Holding Company	2,608,405	8,909,759	2,896,259	7,937,003
Non-controlling interests	219	332	1,941	1,700
	2,608,624	8,910,091	2,898,200	7,938,703

The annexed notes from 1 to 27 form an integral part of these consolidated condensed interim financial statements.

Acr Jon

Asif Jooma Chief Executive



Atif Aboobukar Chief Financial Officer

Consolidated Condensed Interim Statement of Changes in Equity For the Nine Months Period Ended March 31, 2025

	Issued, subscribed and paid-up capital	Capital reserves	Revenue reserve - Unappropriated profit	Total Reserves	Non-controlling interests	Total
			(PKR i	n '000)		
Balance as at July 1, 2023 (Audited)	923,591	309,643	42,458,096	42,767,739	262,906	43,954,236
Profit for the period	-	-	7,937,003	7,937,003	1,700	7,938,703
Other comprehensive income for the period - net of tax Total comprehensive income for the period	-	-	7,937,003	 7,937,003		- 7,938,703
Transaction with owners: Final dividend for the year ended June 30, 2023 @ PKR 33 per share	-	-	(3,047,849)	(3,047,849)	-	(3,047,849) -
Interim dividend for the year ended June 30, 2024 @ PKR 27 per share	-	-	(2,493,694)	(2,493,694)	-	(2,493,694)
Balance as at March 31, 2024 (Unaudited)	923,591	309,643	44,853,556	45,163,199	264,606	46,351,396
Transfer to capital reserves	-	18,000,000	(18,000,000)	-	-	-
Buy back of shares	-	-	-	-	(264,600)	(264,600)
Profit for the period Other comprehensive income for the period - net of tax	-	-	3,213,542 146,688	3,213,542 146,688	10,719	3,224,261 146,688
Total comprehensive income for the period	-	-	3,360,230	3,360,230	10,719	3,370,949
Balance as at June 30, 2024 (Audited)	923,591	18,309,643	30,213,786	48,523,429	10,725	49,457,745
Profit for the period Other comprehensive income for the period - net of tax	-	-	8,909,759 -	8,909,759 -	332 -	8,910,091 -
Total comprehensive income for the period	-	-	8,909,759	8,909,759	332	8,910,091
Transaction with owners: Final dividend for the year ended June 30, 2024 @ PKR 33 per share	-	-	(3,047,849)	(3,047,849)	-	(3,047,849)
Interim dividend for the year ended June 30, 2025 @ PKR 34 per share	-	-	(3,140,208)	(3,140,208)	-	(3,140,208)
As at March 31, 2025 (Unaudited)	923,591	18,309,643	32,935,488	51,245,131	11,057	52,179,779

The annexed notes from 1 to 27 form an integral part of these consolidated condensed interim financial statements.

Consolidated Condensed Interim Statement of Cash Flows (Unaudited) For the Nine Months Period Ended March 31, 2025

	Note	March 31, 2025	March 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES		(PKR in	'000)
Cash generated from operations	22	19,587,303	22,131,179
Payments for :		<i>(</i>)	(00 00)
Non-management staff gratuity and eligible retired employees' medical sch	eme	(32,063)	(23,703)
Staff retirement benefit plan Income taxes and final taxes		(57,308) (4,822,118)	(47,868) (2,983,945)
Interest		(1,359,600)	(2,963,943) (2,770,732)
Net cash generated from operating activities		13,316,214	16,304,931
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure		(7,520,900)	(3,789,494)
Payment for acquisition of business	5	(6,311,649)	-
Proceeds from disposal of operating fixed assets		290,910	17,532
Interest income received		179,730	440,059
Short-term investments made		(265,000)	-
Income received on short term investments		291,622	2,018,931
Net cash used in investing activities		(13,335,287)	(1,312,972)
CASH FLOWS FROM FINANCING ACTIVITIES			
Long-term loans obtained	[7,140,551	669,913
Long-term loans repaid		(821,196)	(1,027,411)
Export refinance facility repaid		(117,578)	(62,000)
Payment of lease liabilities		(156,577)	(84,359)
Dividends paid Net cash generated used in financing activities		(6,167,002) (121,802)	(5,527,905) (6,031,762)
Net cash generated used in financing activities		(121,002)	(0,031,702)
Net (decrease) / increase in cash and cash equivalents		(140,875)	8,960,197
Cash and cash equivalents at the beginning of the period		7,942,563	581,314
Cash and cash equivalents at the end of the period	•	7,801,688	9,541,511
Cash and cash equivalents at the end of period comprise of:			
Cash and bank balances		735,517	1,283,171
Short term investments	12	18,370,535	14,925,440
Short-term running finance	16	(11,304,364)	(6,667,100)
	:	7,801,688	9,541,511

The annexed notes from 1 to 27 form an integral part of these consolidated condensed interim financial statements.

Muhammad Sohail Tabba Chairman / Director

Ach Jon

Asif Jooma Chief Executive

Atif Aboobukar Chief Financial Officer

Notes to and Forming Part of the Consolidated Condensed Interim Financial Statements (Unaudited)

For the Nine Months Period Ended March 31, 2025

1. STATUS AND NATURE OF BUSINESS

The Group consists of Lucky Core Industries Limited (the "Holding Company") and the following subsidiaries:

- Lucky Core PowerGen Limited ("PowerGen");
- Lucky TG (Private) Limited ("Lucky TG"); and
- Lucky Core Venture (Private) Limited ("LCV").

The Holding Company was incorporated in Pakistan and is listed on the Pakistan Stock Exchange Limited. The Holding Company's registered office is situated at 5 West Wharf, Karachi. The Holding Company is engaged in the manufacturing of polyester staple fibre, POY chips, soda ash, specialty chemicals, sodium bicarbonate and polyurethanes; marketing of seeds, toll manufactured and imported pharmaceuticals and animal health products; and merchanting of general chemicals and manufacturing of Masterbatches. It also acts as an indenting agent and toll manufacturer. The Holding Company is the subsidiary of Lucky Cement Limited.

PowerGen was incorporated in Pakistan as an unlisted public company and is a wholly owned subsidiary of the Holding Company. PowerGen is engaged in generating, selling and supplying electricity to the Group.

Lucky TG was incorporated in Pakistan as a private company as part of the agreement with Tariq Glass Industries Limited to set up a green field state-of-the-art float glass manufacturing facility. The Holding Company holds 51% of the shares of Lucky TG.

LCV was incorporated in Pakistan as a private company and is a wholly owned subsidiary of the Holding Company. The principal line of the business is to function as holding company of its subsidiaries and associated companies and render advisory services for promotion of their business, development and marketing for the Group.

NutriCo Morinaga (Private) Limited ("NutriCo Morinaga") is the associate of the Holding Company which is involved in manufacturing and trading of infant and grown up formula.

The consolidated condensed interim financial statements comprise the consolidated statement of financial position of Lucky Core Industries Limited and its subsidiary companies, Lucky Core PowerGen Limited, Lucky TG (Private) Limited and Lucky Core Venture (Private) Limited, as at March 31, 2025 and the related consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flow together with the notes forming part thereof.

2. STATEMENT OF COMPLIANCE

- 2.1 These consolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 'Interim Financial Reporting' (IAS 34), issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 (the Act) and provisions of and directives issued under the Act. Where the provisions of and directives issued under the Act differ with the requirement of IAS 34, the provisions of and directives issued under the Act differ with the requirement of IAS 34, the provisions of and directives issued under the Act have been followed.
- **2.2** These consolidated condensed interim financial statements are unaudited and are being submitted to the shareholders as required under section 237 of the Act. These consolidated condensed interim financial statements do not include all the information and disclosures required in the annual audited consolidated financial statements, and should be read in conjunction with the annual audited consolidated financial statements of the Group for the year ended June 30, 2024.

3. MATERIAL ACCOUNTING POLICY INFORMATION

- **3.1** The material accounting policies applied in the preparation of these consolidated condensed interim financial statements are consistent with those followed in the preparation of the Group's annual audited consolidated financial statements for the year ended June 30, 2024.
- **3.2** Taxes on income in the interim periods are accrued using the tax rate that would be applicable to the expected total annual profit or loss.

3.3 NEW STANDARDS, AMENDMENTS TO ACCOUNTING AND REPORTING STANDARDS AND NEW INTERPRETATIONS

3.3.1 Amendments and interpretations to accounting and reporting standards that are effective in the current period

There are certain new amendments and interpretations to the accounting and reporting standards which are mandatory for the Group during the current period. However, these do not have any significant impact on the Group's financial statements and therefore are not disclosed in these consolidated condensed interim financial statements.

3.3.2 Standards, amendments and interpretations to accounting and reporting standards that are not yet effective

There are certain new and amended standards, interpretations and amendments that are mandatory for the Group's accounting periods beginning on or after July 1, 2025 but are considered not to be relevant or will not have any significant effect on the Group's operations and therefore are not disclosed in these consolidated condensed interim financial statements except for the following:

- The new standard - IFRS 18 'Presentation and Disclosure in Financial Statements' (IFRS 18) (published in April 2024 with applicability date of January 1, 2027 by IASB. IFRS 18 when adopted and applicable shall impact the presentation of 'Statement of Profit or Loss' with certain additional disclosures in the financial statements;

- The new standards - IFRS S1 'General Requirements for Disclosure of Sustainability-related Financial Information' (IFRS S1) (published in June 2023) and IFRS S2 'Climate-related Disclosures' (IFRS S2) (published in June 2023) with applicability dates of July 1, 2025 by Securities and Exchange Comission of Pakistan. IFRS S1 and IFRS S2 when adopted and applicable shall require discloses of information about sustainability-related risks and oppurtunities and climate-related risks and oppurtunities respectively; and

- Amendments to IFRS 9 'Financial Instruments' which clarify the date of recognition and derecognition of a financial asset or financial liability including settlement of liabilities through banking instruments and channels including electronic transfers. The amendment when applied may impact the timing of recognition and derecognition of financial liabilities.

The management is in the process of accessing the impacts of the new standards and the amendments on the financial statements of the Group.

4. ACCOUNTING ESTIMATES AND JUDGMENTS

Preparation of consolidated ondensed interim financial statements in conformity with the accounting and reporting standards as applicable in Pakistan requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities and incomes and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to estimates are recognised prospectively. In preparing these consolidated condensed interim financial statements, the significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended June 30, 2024.

5. BUSINESS ACQUISITION

5.1 In line with the Group's growth aspirations and strategic priorities, the Holding Company acquired a manufacturing facility, selected pharmaceutical products, brands and associated trademarks of Pfizer Pakistan Limited, for a total consideration of PKR 5,000 million. In addition to this the Holding Company also acquired relevant working capital along with inventory for a consideration of PKR 2,437 million out of which PKR 1,125 million relates to deferred consideration which is payable after one year from the acquisition date. The transaction was successfully completed on September 6, 2024 (acquisition date).

As per the requirements of International Financial Reporting Standard 3 – "Business Combinations" (IFRS 3), all identifiable assets acquired and liabilities assumed in business combination are required to be recognised at acquisition date at fair value in the acquirer's statement of financial position. IFRS 3 also allows an acquirer to disclose provisional values when the initial accounting for a business combination is incomplete at the end of the reporting period, which is required to be finalised within the period of one year from the acquisition date.

The Holding Company has recorded the identifiable assets at provisional values, as allowed under IFRS 3, because the necessary valuations and calculations not finalised as at the reporting date. Any adjustment in the provisional values of identifiable assets will be adjusted in the financial statements of the Holding Company retrospectively from the acquisition date.

Details of the provisional fair values of the assets acquired are as follows: 5.2

	Fair value recognised on acquisition
Indicative value of tangible accete:	(PKR in '000)
Indicative value of tangible assets:	
Leasehold land	1,500,800
Building on leasehold land	385,013
Plant, machinery and equipment	1,728,549
Vehicles - net	115,255
Total non-current assets	3,729,617
Current assets	153,519
	3,883,136
Indicative value of intangible assets:	
Brands	1,289,047
	5,172,183
Working capital including inventory	2,436,970
Total assets	7,609,153

5.3 Details of the carrying values of the net assets acquired, purchase consideration and gain on bargain purchase are as follows:

	September 06, 2024 (PKR in '000)
Fair value of net assets acquired	5,172,183
Purchase consideration - paid in cash	(5,000,000)
Gain on bargain purchase	172,183

5.4 Net turnover and operating profit from the acquired business during the period ended March 31, 2025 are as follows:

	(PKR in '000)
Net turnover	5,152,767
Operating profit	1,133,974

The aforementioned results have been reported under the Pharma segment of the Holding Company based on the accounting policies of the Holding Company as disclosed in the consolidated annual financial statements for the year ended June 30, 2024.

6.	PROPERTY, PLANT AND EQUIPMENT	Note	March 31, 2025 (Unaudited) (PKR ir	June 30, 2024 (Audited) 1 '000)
	Operating fixed assets - at net book value Capital work-in-progress - at cost Total property, plant and equipment	6.3	26,449,630 11,798,342 38,247,972	24,391,563 5,538,233 29,929,796
6.1	Following is the movement in property, plant and equipment during the period	l / year:		
	Operating fixed assets (WDV) - opening balance Add: Additions / transfers during the period / year Add: Business acquisition during the period / year	6.2 5.2	24,391,563 1,243,410 <u>3,729,617</u> 29,364,590	24,736,363 3,020,627 - 27,756,990
	Less: Disposals during the period / year (WDV) Less: Depreciation charge for the period / year Operating fixed assets (WDV) - closing balance Add: Capital work-in-progress	6.2 6.3	(199,438) (2,715,522) 26,449,630 11,798,342 38,247,972	(19,695) (3,345,732) 24,391,563 5,538,233 29,929,796

6.2 Following are the details of operating fixed assets that have been added / transferred and disposed off during the period / year:

	Additions	Transfers	Disposals at	net book value
	For the period ended March 31, 2025 (Unaudited)	For the year ended June 30, 2024 (Audited)	For the period ended March 31, 2025 (Unaudited)	For the year ended June 30, 2024 (Audited)
		(PKR	in '000)	
Leasehold land	63,254	-	-	-
Lime beds on freehold land	-	265,112	-	-
Buildings on freehold land	93,311	103,406	-	-
Buildings on leasehold land	41,121	529,996	143	1,502
Plant and machinery	881,734	1,868,072	85,064	14,827
Rolling stock and vehicles	- -	20,235	110,665	-
Furniture and equipment	163,990	233,806	3,566	3,365
	1,243,410	3,020,627	199,438	19,695

6.3 Following is the movement in capital work-in-progress during the period / year:

		Pe	riod ended March	31, 2025 (Unaud	ited)	
	Civil works and buildings	Plant and machinery	Furniture and equipment	Advances to suppliers / contractors	Designing, consultancy and engineering fee	Total
			(PKR	in '000)		
Opening balance Additions during the period Transferred to operating fixed assets during the period	377,622 1,045,872 (156,743)	1,869,046 3,819,219 (788,202)	611,430 491,586 (141,134)	1,999,813 1,489,689 (30,165)	680,322 554,644 (24,657)	5,538,233 7,401,010 (1,140,901)
Transfers between categories Closing balance - note 6.3.1	100,829 1,367,580	2,645,478 7,545,541	2,081 963,963	(2,748,912) 710,425	524 1,210,833	- 11,798,342
			Year ended June	30, 2024 (Audite	d)	
	Civil works and buildings	Plant and machinery	Furniture and equipment	Advances to suppliers / contractors	Designing, consultancy and engineering fee	Total
			(PKR	in '000)		
Opening balance Additions during the year Transferred to operating fixed	47,611 1,104,866	1,611,820 1,739,434	121,229 618,717	838,283 1,489,623	242,984 648,330	2,861,927 5,600,970
assets during the year Closing balance	(774,855) 377,622	(1,482,208) 1,869,046	(128,516) 611,430	(328,093) 1,999,813	(210,992) 680,322	(2,924,664) 5,538,233

6.3.1 Majority of the closing balance of capital work-in-progress pertains to projects relating to Soda Ash business.

7.	INTANGIBLE ASSETS	Note	March 31, 2025 <u>(Unaudited)</u> (PKR in	June 30, 2024 (Audited) 1 '000)
	Intangible assets - at net book value	7.1	2,979,001	1,682,954
7.1	Following are the details of intangible assets: Brands Goodwill Others		2,726,726 206,374 45,901 2,979,001	1,437,679 206,374 38,901 1,682,954
7.2	Additions to intangible assets	7.3	1,306,429	31,066

7.3 This mainly includes additions as a result of business acquisition as disclosed in note 5.2 of these consolidated condensed interim financial statements.

8.	Note LONG-TERM INVESTMENTS	March 31, 2025 <u>(Unaudited)</u> (PKR i	June 30, 2024 <u>(Audited)</u> n '000)
	Unquoted - at cost Associate - NutriCo Morinaga (Private) Limited [22.2% holding (June 30, 2024: 24.5% holding)] 20,121,621 (June 30, 2024: 20,121,621) ordinary shares 8.1 face value of PKR 100 each	10,853,638	10,824,765
	Others Equity - Arabian Sea Country Club Limited 250,000 (June 30, 2024: 250,000) ordinary shares of PKR 10 each	2,500	2,500
		10,856,138	10,827,265

During the period, NutriCo Morinaga (Private) Limited (NutriCo) issued right shares which were not subscribed / declined by 8.1 the Holding Company which consequently reduced the shareholding percentage of the Holding Company in NutriCo from 24.5% to 22.2%.

9.	STOCK-IN-TRADE	Note	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) 1 '000)
	Raw and packing material includes goods-in-transit amounting to PKR 1,959.793 million (June 30, 2024: PKR 1,917.291 million)		9,862,415	7,959,181
	Work-in-process		594,986	483,585
	Finished goods include goods-in-transit amounting to PKR 328.669 million			
	(June 30, 2024: PKR 485.710 million)	9.1	8,234,392	7,253,716
			18,691,793	15,696,482
	Provision for slow moving and obsolete stock-in-trade		(174,705)	(230,106)
			18,517,088	15,466,376

Stock amounting to PKR 296.070 million (June 30, 2024: PKR 18.538 million) is measured at net realisable value. The 9.1 related expense amounting to PKR 11.951 million (June 30, 2024: PKR 7.620 million) has been recognised in cost of sales.

10.	TRADE DEBTS	Note	March 31, 2025 (Unaudited) (PKR ir	June 30, 2024 (Audited) 1 '000)
	Considered good			
	- Secured		831,362	2,076,145
	- Unsecured			
	Due from associated companies		51,940	56,389
	Others		5,860,461	4,459,102
			6,743,763	6,591,636
	Considered doubtful		249,406	170,820
			6,993,169	6,762,456
	- Allowance for expected credit loss (ECL)	10.1	(249,406)	(170,820)
	- Provision for price adjustments, discounts and sales returns		(1,033,426)	(998,493)
			(1,282,833)	(1,169,313)
			5,710,336	5,593,143

During the period, the Group has recognised allowance for ECL amounting to PKR 82.561 million (June 30, 2024: PKR 10.1 51.039 million).

11.	OTHER RECEIVABLES	Note	March 31, 2025 <u>(Unaudited)</u> (PKR in	June 30, 2024 (Audited) 1 '000)
	Considered good			
	Sales tax		1,084,968	1,827,731
	Commission and discounts receivable		7,336	3,185
	Due from associated companies		10,826	-
	Accrued interest income		2,818	6,814
	Receivable from principal		133,025	125,407
	Others		185,443	257,770
			1,424,416	2,220,907
	Considered doubtful		90,345	79,699
			1,514,761	2,300,606
	Allowance for ECL		(90,345)	(79,699)
			1,424,416	2,220,907
12.	SHORT TERM INVESTMENTS			
	At fair value through profit or loss			

Investments in mutual funds	12.1	18,370,535	15,582,822
At amortised cost		<u>392,000</u>	127,000
Term deposits receipts		18,762,535	15,709,822

12.1 This includes unrealised revaluation gain of PKR 1,550.692 million (June 30, 2024: Nil) arising on remeasurement of investment in mutual funds.

13.	LONG-TERM LOANS	March 31, 2025 <u>(Unaudited)</u> (PKR i	June 30, 2024 (Audited) n '000)
	Long-term loans	11,369,567	4,895,794
	Current portion shown under current liabilities	(1,054,484)	(909,446)
		10,315,083	3,986,348

13.1 There is no material change in the terms and conditions of the long-term loans as disclosed in the Holding Company's annual audited consolidated financial statements for the year ended June 30, 2024. During the period, the Holding Company has obtained Diminishing Musharakah of PKR 6,867.400 million from various banks to finance acquisition of certain assets of Pfizer Pakistan Limited as explained in note 5 and to manage capital expenditure requirements of its Soda Ash business. Repayment of these loan is to be made in quarterly installments in 7 years including 1 to 2 years of grace period. The mark-up on these loans is charged at KIBOR plus 0.05% to KIBOR plus 0.2% per annum. The loans are secured against fixed assets of the Holding Company.

14.	DEFERRED TAX LIABILITY - NET	March 31, 2025 (Unaudited) (PKR in	June 30, 2024 (Audited) '000)
	Deductible temporary differences		
	Provisions for allowance for ECL and others	(638,176)	(636,120)
	Retirement benefit fund provisions	(136,448)	(140,301)
	Taxable temporary differences		
	Property, plant and equipment and intangibles	2,577,193	2,894,352
	Investment in associate	3,487,368	3,478,995
	Investments in mutual funds	387,454	-
		5,677,391	5,596,926

Report for the Nine Months Ended March 31, 2025

15.	DEFERRED INCOME - GOVERNMENT GRANT	March 31, 2025 _(Unaudited) (PKR in	June 30, 2024 (Audited) 1 '000)
	Government grant Current portion of government grant	709,010 (187,136) 521,874	863,428 (204,473) 658,955
16.	SHORT-TERM FINANCING		
	Export refinance facility (ERF) Short-term running finance - secured	2,400,000 11,304,364 13,704,364	2,517,578 9,216,926 11,734,504

16.1 There is no material change in the terms and conditions of short-term borrowings and running finances as disclosed in the Group's annual audited consolidated financial statements for the year ended June 30, 2024.

		March 31,	June 30,
		2025	2024
		(Unaudited)	(Audited)
17.	CONTINGENCIES AND COMMITMENTS	(PKR in	'000)

17.1 Contingencies

17.1.1 Claims against the Group not acknowledged as debt are as follows:

Local bodies	84,500	84,500
Others	1,512,755	2,095,740
	1,597,255	2,180,240

- **17.1.2** There are no material changes in the status of contingencies as reported in the annual audited consolidated financial statements for the year ended June 30, 2024, except for the following:
 - (a) The Federal Board of Revenue (FBR) finalised sales tax proceedings vide order dated July 29, 2024, whereby, input tax of PKR 90.860 million was disallowed. Being aggrieved by the order, the Holding Company filed an appeal before the Tribunal which vide appellate order dated December 11, 2024 has remanded back the case to FBR.
 - (b) Sales tax audit for July 2018 to June 2019 has been finalised by the FBR vide order dated October 22, 2024 raising sales tax demand of PKR 23.295 million on various issues including adjustment of inadmissible input tax and non-payment of sales tax on sale of fixed assets. The Holding Company has filed an appeal before the Tribunal which is pending adjudication, however, the sales tax demand has been paid under protest.
 - (c) There has been a dispute between the Holding Company and the Collectorate of Customs regarding HS code classification of various consignments relating to Power Generation Projects. A petition was filed by the Holding Company before the Sindh High Court against the wrong assessment of the consignment along with the submission of bank guarantees for the differential amount of PKR 1,095.290 million with the Nazir of the Sindh High Court in order to release import shipments. Subsequently, the Sindh High Court has disposed off the petition vide order dated January 13, 2025 whereby the case has been remanded back to the Classification Centre for deciding the correct classification of consignment relating to Power Generation Projects. Being aggrieved, the Holding Company has filed a petition before the Supreme Court of Pakistan which is yet to be fixed for hearing.

The Holding Company based on the opinion of advisors is confident that the above cases would be decided in Group's favor. Accordingly, no provision in respect of these matters has been made in these consolidated condensed interim financial statements.

		March 31, 2025	June 30, 2024
17.2	Commitments	<u>(Unaudited)</u> (PKR i	<u>(Audited)</u> n '000)
17.2.1	Commitments in respect of capital expenditure	1,497,018	4,928,711

$\frac{Year}{2023-24} - 6,756$ $2024-25 - 5,067 - 7,195$ $2025-26 - 7,195 - 7,663$ $2026-27 - 7,663 - 8,161$ $2027-28 - 8,161 - 8,69136,777 - 38,466$ Payable not later than one year - 36,777 - 38,466 Payable not later than one year - 33,777 - 38,466 Payable later than one year but not later than five years - 36,777 - 38,466 7.3 Other commitments 7.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) - 10,317,310 - 9,958,727 7.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) - 5,238,925 - 4,407,696 7.3.3 Commitments in respect of post dated cheques - 1,072,955 - 1,081,752	17.2.2 Commitments for rentals under Ijarah contracts in respect of vehicles are as follows:	March 31, 2025 <u>(Unaudited)</u> (PKR in	June 30, 2024 (Audited) 1 '000)
2023-24 - 6,756 2024-25 5,067 7,195 2025-26 7,195 7,663 2026-27 7,663 8,161 2028-29 8,691 - 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year 31,710 31,710 31,710 31,710 36,777 38,466 17.3 Other commitments - - 17.3 Other commitments - - 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696			
2024-25 5,067 7,195 $2025-26$ 7,195 7,663 $2026-27$ 7,663 8,161 $2028-29$ 8,691 - $36,777$ 38,466 Payable not later than one year 5,067 6,756 Payable later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696			
2025-26 7,195 7,663 2026-27 7,663 8,161 2027-28 8,161 8,691 2028-29 - - 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3 Other commitments 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696		-	-
2026-27 7,663 8,161 2027-28 8,691 - 2028-29 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696		,	-
2027-28 8,161 8,691 2028-29 8,691 - 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696		,	,
2028-29 8,691 - 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696			,
Payable not later than one year 36,777 38,466 Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696	2027-28	8,161	8,691
Payable not later than one year 5,067 6,756 Payable later than one year but not later than five years 31,710 31,710 17.3 Other commitments 36,777 38,466 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696	2028-29	8,691	-
Payable later than one year but not later than five years 31,710 17.3 Other commitments 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696		36,777	38,466
Payable later than one year but not later than five years 31,710 17.3 Other commitments 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696			
17.3 Other commitments 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925	Payable not later than one year	5,067	6,756
17.3 Other commitments 17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925	Payable later than one year but not later than five years	31,710	31,710
17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million (June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696		36,777	38,466
(June 30, 2024: PKR 17,331.663 million) 10,317,310 9,958,727 17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925 4,407,696	17.3 Other commitments		
17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million (June 30, 2024: PKR 220.022 million) 5,238,925	17.3.1 Outstanding letter of credit - unutilised PKR 17,345.781 million		
(June 30, 2024: PKR 220.022 million) <u>5,238,925</u> 4,407,696	(June 30, 2024: PKR 17,331.663 million)	10,317,310	9,958,727
(June 30, 2024: PKR 220.022 million) <u>5,238,925</u> 4,407,696			
	17.3.2 Outstanding letter of guarantee - unutilised PKR 145.991 million		
17.3.3 Commitments in respect of post dated cheques 1,072,955 1,081,752	(June 30, 2024: PKR 220.022 million)	5,238,925	4,407,696
17.3.3 Commitments in respect of post dated cheques 1,072,955 1,081,752			
	17.3.3 Commitments in respect of post dated cheques	1,072,955	1,081,752

25 Lucky Core Industries Limited

18. OPERATING SEGMENT RESULTS

		For the nine months period ended March 31, 2024
	Animal Health	For the three months period ended March 31, 2024
	Anima	For the nine For the three For the nine months period months period months period march ended March 31, 2024 31, 2024
		For the three months period ended March 31, 2025
		or the nine Por the three Por the three Por the nine Por
	rma	For the three months period ended March 31, 2024
	Pharma	For the nine months period ended March 31, 2025
dited		For the three months period ended March 31, 2025
Unau		For the nine Fr months period m ended March et 31, 2024
	Soda Ash	For the three months period ended March 31, 2024
Unaudited	Soda	For the three For the three For the three For the nine For the three months period mon
		For the nine months period ended March 31, 2024
	Polyester	For the three months period ended March 31, 2024
	Poly	For the three For the nine For the three For the nine nonthis period months period months period months period arch anded March anded March 31, 2024 31, 2024
		For the three months period ended March 31, 2025

PKR in '000

Turnover - note 18.1, 18.2 & 18.3	11,453,025	37,969,208	12,597,497	35,817,396	12,006,126	36,091,923	13,929,246	42,999,653	6,302,338	19,242,452	4,270,169	12,082,391	2,559,622	7,100,423	2,557,831	7,119,901
Sales tax	(1,721,534)	(5,714,709)	(1,779,693)	(5,065,972)	(1,619,005)	(4,643,891)	(1,689,509)	(5,071,363)	(44,564)	(137,678)	(41,347)	(119,600)	(56,566)	(173,295)	(46,222)	(134,655)
Commission and discounts/ price adjustment	(91,755)	(446,020)	(157,778)	(399,813)	(544,941)	(1,385,140)	(517,387)	(1,701,405)	(1,151,290)	(3,568,912)	(1,074,717)	(3,026,986)	(883,525)	(2,428,658)	(700,112)	(1,844,722)
	(1,813,289)	(6,160,729)	(1,937,471)	(5,465,785)	(2,163,946)	(6,029,031)	(2,206,896)	(6,772,768)	(1,195,854)	(3,706,590)	(1,116,064)	(3,146,586)	(940,091)	(2,601,953)	(746,334)	(1,979,377)
Net turnover	9,639,736	31,808,479	10,660,026	30,351,611	9,842,180	30,062,892	11,722,350	36,226,885	5,106,484	15,535,862	3,154,105	8,935,805	1,619,531	4,498,470	1,811,497	5,140,524
Cost of sales - note 18.1 & 19	(9,035,280)	(29,718,842)	(9,902,090)	(28,750,843)	(7,343,708)	(21,656,868)	(8,338,322)	(26,082,375)	(3,106,664)	(9,524,829)	(1,862,205)	(5,548,378)	(1,050,974)	(2,934,600)	(1,289,867)	(3,631,049)
Gross profit	604,456	2,089,637	757,936	1,600,768	2,498,472	8,406,024	3,384,028	10,144,510	1,999,820	6,011,033	1,291,900	3,387,427	568,557	1,563,870	521,630	1,509,475
Selling and distribution expenses	(85,087)	(239,276)	(56,051)	(172,552)	(334,058)	(1,430,673)	(646,672)	(1,946,867)	(782,456)	(2,099,292)	(519,165)	(1,435,859)	(227,425)	(678,322)	(205,044)	(629,430)
Administration and general expenses	(37,389)	(131,018)	(40,162)	(112,826)	(253,619)	(795,516)	(277,142)	(916,207)	(182,307)	(484,298)	(198,266)	(410,052)	(36,307)	(103,042)	(34,008)	(96,710)
Operating results	481,980	1,719,343	661,723	1,315,390	1,910,795	6,179,835	2,460,214	7,281,436	1,035,057	3,427,443	574,469	1,541,516	304,825	782,506	282,578	783,335

Health	June 30, 2024 (Audited)	
Animal Health	March 31, 2025 (Unaudited)	
ma.	June 30, 2024 (Audited)	
Pharma	March 31, 2025 (Unaudited)	1000.
Ash	June 30, 2024 (Audited)	(PKR i
Soda Ash	March 31, 2025 (Unaudited)	
Polyester	June 30, 2024 (Audited)	
Poly	March 31, 2025 (Unaudited)	

Segment assets

Segment liabilities

7,125,809 1,083,229 5,557,449 10,285,328 19,059,991 12,578,986 51,179,788 10,409,028 11,105,274 57,295,966 14,717,312 16,212,254 17,476,112 14,036,604

784,293 6,182,262

hen	nicals and	Chemicals and Agri Sciences		Others	Gth	Others			Gre	Group	
For	For the nine	For the three	For the nine	For the three	For the nine	For the three	For the nine	For the three	For the nine	For the three	For the nine
mon end	months period ended March	months period ended March	months period ended March	months period ended March	months period ended March	months period ended March					
ŝ	31, 2025	31, 2024	31, 2024	31, 2025	31, 2025	31, 2024	31, 2024	31, 2025	31, 2025	31, 2024	31, 2024
					PKR i	PKR in '000					
÷	12,303,186	4,689,498	13,422,409	376,818	1,319,436	361,784	1,390,517	36,699,202	112,822,938	38,076,305	111,370,562
5	(1,274,034)	(421,058)	(1,231,910)	(57,481)	(201,269)	(55,188)	(212,113)	(3,948,843)	(12,144,875)	(4,033,017)	(11,835,613)
	(799,864)	(553,295)	(1,468,481)	•	•			(2,946,584)	(8,628,594)	(3,003,289)	(8,441,407)
0	(2,073,898)	(974,353)	(2,700,391)	(57,481)	(201,269)	(55,188)	(212,113)	(6,895,427)	(20,773,469)	(7,036,306)	(20,277,020)
-	10,229,288	3,715,145	10,722,018	319,337	1,118,167	306,596	1,178,404	29,803,775	92,049,469	31,039,999	91,093,542
-	(7,411,052)	(2,655,901)	(7,542,895)	(293,611)	(1,031,947)	(283,972)	(1,097,117)	(23,087,054)	(71,072,963)	(24,002,637)	(71,190,951)
	2,818,236	1,059,244	3,179,123	25,726	86,220	22,624	81,287	6,716,721	20,976,506	7,037,362	19,902,591
<u> </u>	(1,068,421)	(427,853)	(1,176,578)					(1,814,706)	(5,515,983)	(1,854,785)	(5,361,286)
	(249,697)	(90,583)	(325,876)	(695)	(2,429)	(29)	(1,894)	(607,303)	(1,766,000)	(640,190)	(1,863,565)
	1,500,118	540,808	1,676,669	25,031	83,791	22,595	79,393	4,294,712	13,694,523	4,542,387	12,677,740
						Chemicals and Agri Sciences	Agri Sciences	Oth	Others	Gre	Group
						March 31, 2025 (Unaudited)	June 30, 2024 (Audited)	March 31, 2025 (Unaudited)	June 30, 2024 (Audited)	March 31, 2025 (Unaudited)	June 30, 2024 (Audited)
								PKR i	(PKR in '000)		
						16,364,579	14,580,686	692,875	755,258	118,015,332 (22,350,104) 10,856,138 106,521,366	99,195,576 (17,647,588) 10,827,265 92,375,253
						2,799,396	2,624,653	2,982,903	296,308	44,586,392 (22,350,104) 32,105,299	34,389,044 (17,647,588) 26,176,052
										24,341,387	42,917,508

Turnover - note 18.1, 18.2 & 18.3 Sales tax

oates tax Commission and discounts/ price adjustment

Net turnover Cost of sales - note 18.1 & 19

Gross profit Selling and distribution expenses Administration and general expenses Operating results

Segment assets Intersegment eliminitions Unallocated assets Segment liabilities Intersegment eliminitions Unallocated liabilities

		For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	March 31, 2024	For the nine months period ended March 31, 2024
			•	dited)	
			(PKR i	in '000)	
18.1	Turnover and cost of sales				
	Inter-segment sales and purchases have been eliminated from the total	336,372	1,203,689	329,720	1,461,705
18.2	Turnover includes export sales made to various countries amounting to:	1,371,494	5,782,067	2,463,712	8,701,673
18.3	Turnover includes commission / toll income amounting to:	22,566	66,047	15,064	20,420
19.	COST OF SALES				
	Opening stock of raw and packing materials - note 9 Purchases	8,748,317 15,255,237	7,959,181 45,536,930	9,251,103 15,703,245	9,927,537 42,435,829
	Closing stock of raw and packing materials - note 9	24,003,554 (9,862,415)	53,496,111 (9,862,415)	24,954,348 (10,171,190)	52,363,366 (10,171,190)
	Raw and packing materials consumed Manufacturing costs	14,141,139 6,603,158	43,633,696 21,935,719	14,783,158 7,587,076	42,192,176 22,242,655
	Opening stock of work-in-process - note 9	20,744,297 716,198	65,569,415 483,585	22,370,234 646,812	64,434,831 450,271
	Closing stock of work-in-process - note 9	21,460,495 (594,986)	66,053,000 (594,986)	23,017,046 (515,714)	64,885,102 (515,714)
	Cost of goods manufactured Opening stock of finished goods - note 9 Finished goods purchased	20,865,509 9,957,371 498,566	65,458,014 7,253,716 6,595,625	22,501,332 6,900,153 797,434	64,369,388 8,407,429 4,610,416
	Closing stock of finished goods - note 9	31,321,446 (8,234,392)	79,307,355 (8,234,392)	30,198,919 (6,196,282)	77,387,233 (6,196,282)
		23,087,054	71,072,963	24,002,637	71,190,951

20. OTHER INCOME

This includes PKR 1,842.303 (March 31, 2024: 2,018.931 million) on account of income from investment in mutual funds.

		For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			•	dited)	
21.	BASIC AND DILUTED EARNINGS PER SHARE		(PKR i	n '000)	
	Profit attributable to the owners of the Holding Company	2,608,405	8,909,759	2,896,259	7,937,003
	Weighted average number of ordinary shares		(Number	of shares)	
	outstanding during the period	92,359,050	92,359,050	92,359,050	92,359,050
			(PI	<pre> (R)</pre>	
	Basic and diluted earnings per share	28.24	96.47	31.36	85.94
	basic and under carrings per share	20.24			00.04

		Note	For the nine months ended March 31, 2025	For the nine months ended March 31, 2024
22.	CASH GENERATED FROM OPERATIONS		(Unau	
			(PKR i	n '000)
	Profit before final taxes and income tax		14,183,063	12,056,928
	Adjustments for:			
	Depreciation and amortisation		2,815,085	2,580,385
	Gain on disposal of operating fixed assets		(91,472)	(14,472)
	Gain on bargain purchase		(172,183)	-
	Provision for non-management staff gratuity and eligible retired			
	employees' medical scheme		32,418	34,476
	Provision for staff retirement benefit plans		40,393	33,412
	Interest income		(175,733)	(309,828)
	Interest expense		1,754,955	2,733,209
	Income from mutual funds		(291,622)	(2,018,931)
	Provisions no longer required written-back		-	(58)
	Provision for slow moving and obsolete stock-in-trade		5,368	101,400
	Allowance for expected credit losses		82,561	32,424
	Unwinding of staff loans		(666,959)	-
	Deferred income - Government grant		(154,418)	(139,573)
	Share of (profit) / loss from associate		(28,873)	106,502
	Provision for slow moving and obsolete stores, spares and consumables		9,370	4,719
			17,341,953	15,200,593
	Movement in:			
	Working capital	22.1	2,305,931	7,049,266
	Long-term loans		(42,900)	(116,909)
	Long-term deposits and other assets		(17,681)	(1,771)
	Cash generated from operations		19,587,303	22,131,179
22.1	Movement in working capital			
	(Increase) / decrease in current assets			
	Stores, spares and consumables		1,133,308	2,372,273
	Stock-in-trade		(1,761,951)	1,800,651
	Trade debts		(199,754)	43,351
	Loans and advances		(374,658)	109,085
	Trade deposits and short-term prepayments		312,735	1,792,782
	Other receivables		792,495	1,562,705
			(97,825)	7,680,847
	Increase / (decrease) in current liabilities			
	Trade and other payables		2,403,756	(631,581)
			2,305,931	7,049,266

23. TRANSACTIONS WITH RELATED PARTIES

The related parties comprise the ultimate Holding company (Lucky Cement Limited) and related group companies, associated companies, directors of the Group, companies where directors also hold directorship, key employees and staff retirement funds. All the transactions with related parties are entered into at agreed terms duly approved by the Board of Directors of the Group. Details of transactions with related parties, other than those which have been specifically disclosed elsewhere in these consolidated condensed interim financial statements are as follows:

Relationship with the Group	Nature of Transaction	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	For the three months period ended March 31, 2024	For the nine months period ended March 31, 2024
			· ·	idited) in '000)	
Parent Company	Dividend paid	1,727,132	3,403,466	1,371,546	3,047,880
	Sale of goods and materials Purchase of goods, materials and	6,908	23,330	11,159	31,526
	services Reimbursement of expenses	51,441 565	156,590 565	17,998 -	38,058 -

Report for the Nine Months Ended March 31, 2025

Relationship with the Group	Nature of Transaction	For the three months period ended March 31, 2025	For the nine months period ended March 31, 2025	March 31, 2024	For the nine months period ended March 31, 2024
			•	dited)	
			(PKR i	in '000)	
	Purchase of goods, materials and				
Associated	services	392,347	626,636	73,351	250,873
Companies	Sale of goods and materials	1,072,728	3,917,551	1,005,863	5,081,422
	Reimbursement of expenses	9,013	34,777	13,063	29,567
	Dividend paid	1,644,261	1,644,261	661,832	1,470,737
	Donations paid	5,158	10,503	945	16,191
Others	Staff retirement benefits - contribution	138,674	391,224	114,386	337,029
Key	Remuneration paid	82,478	502,771	126,454	535,256
management	Post employment benefits	12,730	38,391	13,353	38,958
personnel	Director's meeting fee	959	4,258	1,922	3,816
	Dividend paid	25,136	49,379	19,835	44,078

24. FINANCIAL RISK MANAGEMENT

The Group's financial risk management objective and policies are consistent with that disclosed in the annual audited consolidated financial statements for the year ended June 30, 2024.

25. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction 25.1 between market participants at the measurement date. Consequently, differences can arise between carrying values and the fair value estimates.

Underlying the definition of fair value is the presumption that the Group is a going concern without any intention or requirement to curtail materially the scale of its operations or to undertake a transaction on adverse terms.

The fair value of investments in units of open-end collective investment schemes (mutual funds) are based on the net assets value quoted by the respective funds and the Mutual Funds Association of Pakistan at each reporting date. The estimated fair value of all other financial assets and liabilities are considered not to be significantly different from carrying values as the items are either short-term in nature or are periodically repriced except for lease liabilities.

- 25.2 The Group classifies financial assets using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:
 - (i) Level 1: guoted prices (unadjusted) in active markets for identical assets or liabilities;

(ii) Level 2: inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

(iii) Level 3: inputs for the asset or liability that are not based on observable market data (i.e. unobservable inputs).

As of the reporting date, except for the Group's investment in mutual funds (which is valued under level 2), none of the financial instruments are carried at fair value in these consolidated condensed interim financial statements. There were no transfers between level 1, 2 or 3 of the fair value hierarchy during the year.

	A	s at March 31, 2	2025 (Unaudited	I)
Assets	Level 1	Level 2	Level 3	Total
		(PKR i	n '000)	

Financial assets - fair value through profit or loss: - Short-term investments (units of mutual funds)

		As at June 30,	2024 (Audited)	
Assets	Level 1	Level 2	Level 3	Total
		(PKR i	n '000)	
Financial assets - fair value through profit or loss: - Short-term investments (units of mutual funds)	_	15,582,822	_	15.582.822

26. DATE OF AUTHORISATION

These consolidated condensed interim financial statements were authorised for issue in the Board of Directors meeting held on April 22, 2025.

27. GENERAL

- 27.1 Figures have been rounded off to the nearest thousand PKR except as stated otherwise.
- 27.2 Wherever considered necessary, corresponding figures have been reclassified for the purpose of comparison and improved presentation. However, the impacts are not material.
- 27.3 Non-cash investing and financing activities include additions of right-of-use assets.

Muhammad Sohail Tabba Chairman / Director

Asy Jon

Asif Jooma Chief Executive



Atif Aboobukar Chief Financial Officer

58

A publication of the Corporate Communications & Public Affairs Function

Lucky Core Industries Limited 5 West Wharf Karachi 74000 Pakistan

T + 92 21 3231 3717-22 E ccpa.pakistan@luckycore.com

UAN 111 100 200 www.luckycore.com



